US20230241285A1 - Selectively Polymerizable Compositions and Methods of Use in Vivo - Google Patents
Selectively Polymerizable Compositions and Methods of Use in Vivo Download PDFInfo
- Publication number
- US20230241285A1 US20230241285A1 US18/131,810 US202318131810A US2023241285A1 US 20230241285 A1 US20230241285 A1 US 20230241285A1 US 202318131810 A US202318131810 A US 202318131810A US 2023241285 A1 US2023241285 A1 US 2023241285A1
- Authority
- US
- United States
- Prior art keywords
- polymer
- composition
- scaffold
- methacrylated
- hyaluronic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims description 108
- 238000000034 method Methods 0.000 title abstract description 40
- 238000001727 in vivo Methods 0.000 title description 8
- 229920000642 polymer Polymers 0.000 claims abstract description 147
- 239000007788 liquid Substances 0.000 claims abstract description 69
- 210000003454 tympanic membrane Anatomy 0.000 claims abstract description 44
- 229920001661 Chitosan Polymers 0.000 claims description 52
- 229920002674 hyaluronan Polymers 0.000 claims description 52
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 50
- 229960003160 hyaluronic acid Drugs 0.000 claims description 50
- 229920001730 Moisture cure polyurethane Polymers 0.000 claims description 46
- 239000003999 initiator Substances 0.000 claims description 30
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 claims description 26
- 239000002904 solvent Substances 0.000 claims description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 229960003405 ciprofloxacin Drugs 0.000 claims description 13
- OHSHFZJLPYLRIP-BMZHGHOISA-M Riboflavin sodium phosphate Chemical compound [Na+].OP(=O)([O-])OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O OHSHFZJLPYLRIP-BMZHGHOISA-M 0.000 claims description 12
- 230000001225 therapeutic effect Effects 0.000 claims description 6
- VNQXSTWCDUXYEZ-UHFFFAOYSA-N 1,7,7-trimethylbicyclo[2.2.1]heptane-2,3-dione Chemical compound C1CC2(C)C(=O)C(=O)C1C2(C)C VNQXSTWCDUXYEZ-UHFFFAOYSA-N 0.000 claims description 5
- 239000003242 anti bacterial agent Substances 0.000 claims description 5
- 229930006711 bornane-2,3-dione Natural products 0.000 claims description 5
- GJKGAPPUXSSCFI-UHFFFAOYSA-N 2-Hydroxy-4'-(2-hydroxyethoxy)-2-methylpropiophenone Chemical group CC(C)(O)C(=O)C1=CC=C(OCCO)C=C1 GJKGAPPUXSSCFI-UHFFFAOYSA-N 0.000 claims description 4
- 230000003115 biocidal effect Effects 0.000 claims description 4
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 3
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims description 2
- 230000004913 activation Effects 0.000 claims description 2
- SEACYXSIPDVVMV-UHFFFAOYSA-L eosin Y Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C([O-])=C(Br)C=C21 SEACYXSIPDVVMV-UHFFFAOYSA-L 0.000 claims 1
- 239000000463 material Substances 0.000 abstract description 65
- 239000003814 drug Substances 0.000 abstract description 50
- 239000000499 gel Substances 0.000 abstract description 48
- 229940079593 drug Drugs 0.000 abstract description 46
- 239000000017 hydrogel Substances 0.000 abstract description 39
- 210000000959 ear middle Anatomy 0.000 abstract description 23
- 230000001684 chronic effect Effects 0.000 abstract description 12
- 210000002919 epithelial cell Anatomy 0.000 abstract description 9
- 230000010261 cell growth Effects 0.000 abstract description 7
- 206010045210 Tympanic Membrane Perforation Diseases 0.000 abstract description 6
- 230000008439 repair process Effects 0.000 abstract description 6
- 238000002560 therapeutic procedure Methods 0.000 abstract description 5
- 206010033078 Otitis media Diseases 0.000 abstract description 2
- 230000004888 barrier function Effects 0.000 abstract description 2
- 210000000883 ear external Anatomy 0.000 abstract description 2
- 208000022760 infectious otitis media Diseases 0.000 abstract description 2
- 230000002792 vascular Effects 0.000 abstract description 2
- 239000011800 void material Substances 0.000 abstract description 2
- 230000004956 cell adhesive effect Effects 0.000 abstract 1
- 229920001223 polyethylene glycol Polymers 0.000 description 45
- 239000011159 matrix material Substances 0.000 description 40
- 239000000243 solution Substances 0.000 description 38
- 239000002202 Polyethylene glycol Substances 0.000 description 34
- 238000012856 packing Methods 0.000 description 19
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 18
- -1 Polyethylene Polymers 0.000 description 18
- 238000006116 polymerization reaction Methods 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 15
- 230000003213 activating effect Effects 0.000 description 14
- 230000015572 biosynthetic process Effects 0.000 description 13
- 230000015556 catabolic process Effects 0.000 description 12
- 230000008859 change Effects 0.000 description 12
- 238000006731 degradation reaction Methods 0.000 description 12
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 11
- 229940098773 bovine serum albumin Drugs 0.000 description 10
- 239000011148 porous material Substances 0.000 description 10
- 239000000126 substance Substances 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- 238000004132 cross linking Methods 0.000 description 8
- 125000000524 functional group Chemical group 0.000 description 8
- FZUGPQWGEGAKET-UHFFFAOYSA-N parbenate Chemical compound CCOC(=O)C1=CC=C(N(C)C)C=C1 FZUGPQWGEGAKET-UHFFFAOYSA-N 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 230000021164 cell adhesion Effects 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 108010010803 Gelatin Proteins 0.000 description 6
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 229920000159 gelatin Polymers 0.000 description 6
- 235000019322 gelatine Nutrition 0.000 description 6
- 235000011852 gelatine desserts Nutrition 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 238000001356 surgical procedure Methods 0.000 description 6
- 238000013459 approach Methods 0.000 description 5
- 239000008273 gelatin Substances 0.000 description 5
- 238000001879 gelation Methods 0.000 description 5
- 150000004676 glycans Chemical class 0.000 description 5
- CERQOIWHTDAKMF-UHFFFAOYSA-M methacrylate group Chemical group C(C(=C)C)(=O)[O-] CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 5
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 4
- 125000004386 diacrylate group Chemical group 0.000 description 4
- 210000000613 ear canal Anatomy 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 230000007613 environmental effect Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000003102 growth factor Substances 0.000 description 4
- 230000035876 healing Effects 0.000 description 4
- 238000011065 in-situ storage Methods 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 238000011068 loading method Methods 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 241000700114 Chinchillidae Species 0.000 description 3
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 102000016943 Muramidase Human genes 0.000 description 3
- 108010014251 Muramidase Proteins 0.000 description 3
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000001070 adhesive effect Effects 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000001186 cumulative effect Effects 0.000 description 3
- 239000005548 dental material Substances 0.000 description 3
- 238000012377 drug delivery Methods 0.000 description 3
- 239000003221 ear drop Substances 0.000 description 3
- 229940047652 ear drops Drugs 0.000 description 3
- FVTCRASFADXXNN-SCRDCRAPSA-N flavin mononucleotide Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-SCRDCRAPSA-N 0.000 description 3
- 229960000274 lysozyme Drugs 0.000 description 3
- 235000010335 lysozyme Nutrition 0.000 description 3
- 239000004325 lysozyme Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 231100001223 noncarcinogenic Toxicity 0.000 description 3
- 231100000065 noncytotoxic Toxicity 0.000 description 3
- 230000002020 noncytotoxic effect Effects 0.000 description 3
- 239000002861 polymer material Substances 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 229960002477 riboflavin Drugs 0.000 description 3
- 235000019192 riboflavin Nutrition 0.000 description 3
- 239000002151 riboflavin Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000036962 time dependent Effects 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000005141 Otitis Diseases 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 230000012292 cell migration Effects 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000011461 current therapy Methods 0.000 description 2
- 230000020176 deacylation Effects 0.000 description 2
- 238000005947 deacylation reaction Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 208000019258 ear infection Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000001678 irradiating effect Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 238000012667 polymer degradation Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000010069 protein adhesion Effects 0.000 description 2
- 235000015170 shellfish Nutrition 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- NNRFRJQMBSBXGO-CIUDSAMLSA-N (3s)-3-[[2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]-4-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-oxobutanoic acid Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O NNRFRJQMBSBXGO-CIUDSAMLSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- MUZDXNQOSGWMJJ-UHFFFAOYSA-N 2-methylprop-2-enoic acid;prop-2-enoic acid Chemical compound OC(=O)C=C.CC(=C)C(O)=O MUZDXNQOSGWMJJ-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 229910001369 Brass Inorganic materials 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 108010066486 EGF Family of Proteins Proteins 0.000 description 1
- 102000018386 EGF Family of Proteins Human genes 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101000829980 Homo sapiens Ral guanine nucleotide dissociation stimulator Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000007547 Laminin Human genes 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- 241001124320 Leonis Species 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 102100023320 Ral guanine nucleotide dissociation stimulator Human genes 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 239000010951 brass Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 229940107200 chondroitin sulfates Drugs 0.000 description 1
- 229940021285 ciprodex Drugs 0.000 description 1
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 1
- 229960004022 clotrimazole Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000013267 controlled drug release Methods 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 210000000624 ear auricle Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 210000003195 fascia Anatomy 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- FVTCRASFADXXNN-UHFFFAOYSA-N flavin mononucleotide Natural products OP(=O)(O)OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-UHFFFAOYSA-N 0.000 description 1
- 229940124307 fluoroquinolone Drugs 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000013101 initial test Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- DCUFMVPCXCSVNP-UHFFFAOYSA-N methacrylic anhydride Chemical compound CC(=C)C(=O)OC(=O)C(C)=C DCUFMVPCXCSVNP-UHFFFAOYSA-N 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 231100001200 nonototoxic Toxicity 0.000 description 1
- 229960000988 nystatin Drugs 0.000 description 1
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
- 231100000199 ototoxic Toxicity 0.000 description 1
- 230000002970 ototoxic effect Effects 0.000 description 1
- 229940124641 pain reliever Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229920001798 poly[2-(acrylamido)-2-methyl-1-propanesulfonic acid] polymer Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000671 polyethylene glycol diacrylate Polymers 0.000 description 1
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 1
- 229920002959 polymer blend Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000007348 radical reaction Methods 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 238000005476 soldering Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000013269 sustained drug release Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- WGTODYJZXSJIAG-UHFFFAOYSA-N tetramethylrhodamine chloride Chemical compound [Cl-].C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C(O)=O WGTODYJZXSJIAG-UHFFFAOYSA-N 0.000 description 1
- FUSNMLFNXJSCDI-UHFFFAOYSA-N tolnaftate Chemical compound C=1C=C2C=CC=CC2=CC=1OC(=S)N(C)C1=CC=CC(C)=C1 FUSNMLFNXJSCDI-UHFFFAOYSA-N 0.000 description 1
- 229960004880 tolnaftate Drugs 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
- A61K38/385—Serum albumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/20—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/52—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/56—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
- A61N5/062—Photodynamic therapy, i.e. excitation of an agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/14—Materials or treatment for tissue regeneration for ear reconstruction or ear implants, e.g. implantable hearing aids
Definitions
- the fibrous tissue around the perforation is abraded to induce an inflammatory response.
- the perforation is small such as about 20% or less of the cross-sectional area of the TM, the perforation can be packed with either paper or fat taken from the earlobe. Larger perforations require a more substantial packing material, such as autografts of cartilage or fascia, surgical gelatin, or a synthetic polymer patch. All of these therapies require some kind of surgery, and the success rate of the therapy is highly dependent upon the skill of the surgeon.
- Gelfoam® a type of surgical gelatin obtained from pigs used as a packing material for the middle ear after surgery.
- Gelfoam® is used to fill the void in the middle ear.
- Gelfoam® liquefies when hydrated, and is degraded and cleared easily by the body.
- TM perforation heals, it also provides a surface to which autografts or patches may adhere.
- some patients may be allergic to this material.
- Merogel® a fibrous packing material similar to that of Gelfoam®, but is instead made of hyaluronic acid.
- Merogel® turns into a gel when hydrated, and is easily degraded. It has the same properties as Gelfoam®, but without the risk of allergic reaction due to porcine gelatin. Like Gelfoam®, it is used to pack the middle ear prior to insertion of an autograft or patch, and is not used as a stand-alone treatment.
- Medtronic ENT/Xomed also manufactures EpiOiscTM, a porous hyaluronic patch intended to repair tympanic membranes. It is biodegradable and induces both epithelial cell growth and vascular in-growth of the tympanic membrane. However, to use this patch, it must be trimmed to the size of the perforation and inserted surgically. Occasionally, the patch fails to adhere completely to the native tissue or packing material in the middle ear, resulting in additional surgery to replace the patch.
- the present invention provides selectively polymerizable materials and methods of use in vivo.
- the present invention provides selectively polymerizable otologic materials and methods of use of the materials in the ear of a patient.
- the otologic materials are a liquid pre-polymer composition comprising at least a first polymer (capable of selectively curing/selectively assembling into a polymer matrix under defined conditions in the ear of a patient) and a solvent.
- the otologic materials are a liquid pre-polymer composition comprising at least a first polymer, a solvent and an initiator which when activated in situ in the ear of a patient, results in the repairing or aiding in the repair of a tympanic membrane perforation.
- the liquid pre-polymer composition also comprises a therapeutic composition.
- the polymer matrix has a porosity and an average pore size compatible with releasing the therapeutic composition over a desired time period.
- the polymer matrix may be in the form of a gel such as a hydrogel, and may have a stiffness sufficient to function as a scaffold on which epithelial cells of the tympanic membrane can migrate, adhere and grow.
- the at least first polymer is functionalized such that the resulting polymer matrix has a cell-binding domain, for example, which may improve cell migration and adhesion.
- the initiator is a photoinitiator which is activated by light, for example visible, ultraviolet, infrared, or blue light.
- the at least first polymer is chosen from polyethylene glycols (PEGs) and polysaccharides such as methacrylated chitosan, hyaluronic acid and methacrylated hyaluronic acid.
- the at least first polymer is one or more PEGs.
- the at least first polymer is a methacrylated chitosan and hyaluronic acid.
- the at least first polymer is a methacrylated chitosan and a methacrylated hyalauric acid.
- the at least first polymer is a PEG in combination with at least one of a chitosan or a hyaluronic acid.
- the otologic methods include treating a perforation of the tympanic membrane by administering a liquid pre-polymer composition comprising at least a first polymer, a solvent and optionally an initiator (for example if required to activate the assembly of the at least first polymer into a polymer matrix) to the site of the perforation, and activating the composition (for example activating the initiator) resulting in the liquid composition assembling into a polymer matrix, such as a hydrogel.
- the liquid composition also includes a therapeutic composition.
- the method involves administering a sufficient amount of the liquid composition to at least cover the perforation.
- activating involves exposing the liquid composition to light such as blue light, visible light, infrared (IR) light or ultraviolet (UV) light.
- activating involves exposing the composition to a change of temperature or a change of pH or a change of ion concentration for example such as may be found in the natural environment of the ear.
- activating involves exposing the liquid composition to chemical radical initiators.
- Other methods of activating the liquid compositions are also within scope of this disclosure provided they are biocompatible and suitable for the specific purpose, such as use in repairing perforations of tympanic membranes, or such as timed release delivery of drugs in the ear.
- the otologic methods involve enhancing existing otologic packing materials by administering liquid pre-polymer compositions described herein to the packing materials and curing or assembling the liquid pre-polymer compositions after administration.
- the otologic packing materials are first administered to a desired site in a patient's ear prior to administering the liquid pre-polymer compositions.
- the methods and materials may accomplish one or more of the following objects:
- FIG. 1 is a graph illustrating a quantification of bovine serum albumin released from exemplary PEG hydrogels of two different molecular weights over time.
- FIG. 2 is a graph illustrating Ciprofloxacin release from 2% MeCS and 2% MeCS/1% HA in 0.5% lysozyme in water.
- FIG. 3 is a graph illustrating Cumulative release of ciprofloxacin from 2% MeCS and 2% MeCS/1% HA in 0.5% lysozyme in water.
- liquid pre-polymer composition or alternatively “pre-polymerization solution” mean the same thing and refer to a composition (comprising at least one polymer) which is capable of being activated to assemble into a more viscous form but that has not yet so assembled.
- a “liquid pre-polymer composition” need not be liquid but only less viscous than its assembled form.
- a “liquid pre-polymer composition” is sufficiently viscous such that it can be positioned to cover a perforation without falling through to the middle ear cavity.
- scaffold refers to a “polymer matrix” having properties compatible with treating a perforation of the tympanic membrane such as by having a stiffness compatible with the migration and growth of epithelial cells on or in the scaffold, and/or by having a porosity compatible with releasing a therapeutic composition, which was part of the liquid pre-polymer composition for example according to a desired time-dependent profile.
- polymerization means the transition of materials, such as otologic materials, according to this disclosure from a liquid pre-polymer to a harder or tougher form such as a gel, solid, or interpenetrating polymer network, which may result from activating the materials such as by adding an assembling agent or curing agent (and activating the agent by for example light, pH, body fluids, temperature, other chemical changes, etc.) or having the pre-polymer assemble or cure through existing natural conditions (for example activating the assembly of the polymers in the liquid pre-polymer composition into a polymer matrix due to the presence of body fluids or existing conditions for example of pH or temperature or ion concentration at the site of administration).
- a polymer such as “chitosan,” “polyethylene glycol,” or “hyaluronic acid,” (as well as reference to those polymers in plural, such as “chitosans,” “polyethylene glycols,” and “hyaluronic acids”) is understood to be reference to a class of polymers, unless in context it is clear that only the basic (backbone) polymer is intended.
- chitosan means chitosan and its derivatives and analogs (for example methacrylated chitosan)
- polyethylene glycol refers to polyethylene glycol, its derivatives and analogs
- hyaluronic acid means hyaluronic acid, its derivatives and analogs.
- the present disclosure provides otologic materials and methods.
- the otologic materials and methods are directed at treating perforations of the tympanic membrane (TM), including chronic perforations of the TM.
- the otologic materials comprise a liquid pre-polymer composition that is cured/assembled in situ resulting in a polymer matrix, for example in the form of a hydrogel scaffold.
- the otologic materials are loaded with drugs, for example for direct delivery to the middle ear to prevent infection, for example recurring infection.
- the methods comprise administering the otologic liquid pre-polymer materials to a desired site in a patient's ear and curing/assembling the materials in situ.
- the methods comprise administering the liquid pre-polymer materials to an otologic packing material and curing/assembling the liquid pre-polymer materials after administration to the packing material.
- Materials according to this disclosure include liquid pre-polymer compositions, which can be cured/assembled into a polymer matrix.
- the materials also include the resultant polymer matrix itself.
- the polymer matrix is a scaffold having sufficient stiffness and/or tackiness (for example as a result of functional groups providing cell adhesion domains) such that epithelial cells in the TM can migrate into and/or onto the scaffold and adhere and/or grow.
- the polymer matrix or scaffold eventually degrades in situ, i.e. is biodegradable, for example after the epithelial cells have grown sufficiently to repair the perforation.
- the liquid pre-polymer composition is designed to cure/assemble into a polymer matrix or scaffold having a porosity and average pore size compatible with loading the resultant polymer matrix or scaffold with a therapeutic agent.
- the porosity and average pore size are chosen to provide a desired time-dependent release profile for the loaded therapeutic agent.
- the otologic materials according to this disclosure are initially a pre-polymer liquid composition for easy administration to a desired site in a patient's ear, and are configured to cure/assemble into a polymer matrix in vivo in the ear of a patient upon activation.
- the liquid pre-polymer compositions include one or more polymers capable of selectively assembling into a polymer matrix at a desired time under specific conditions (for example conditions found in the ear, such as the middle ear), and a solvent.
- the liquid pre-polymer composition may include an initiator, such as a photoinitiator, and the polymers in the liquid pre-polymer composition may be selectively assembled by exposing the composition to light thereby activating the initiator resulting in curing/assembling the pre-polymer composition into a polymer matrix.
- the polymers may be functionalized with methacrylate groups to give them cross-linkability, and riboflavin (a non-carcinogenic, non-cytotoxic photoinitiator) may be added to the liquid pre-polymer composition to initiate the cross-linking of the methacrylate groups in the presence of light.
- composition ingredients are chosen to be biocompatible and suitable for use in the ear, for example the external auditory canal, middle ear, or both.
- the ingredients are chosen such that the resultant polymer matrix is biodegradable, and may be processed and cleared by the body.
- the components chosen are biodegradable, biocompatible, and may be expelled by the kidneys.
- the liquid pre-polymer composition includes at least a first polymer capable of assembling into a polymer matrix, e.g. capable of being cured/assembled such as capable of reacting under defined conditions to form a polymer matrix.
- the polymer may include functional groups that can associate to form a network, for example through formation of covalent bonds, physical bonds, or combinations of both.
- the functional groups on the polymer may determine how it can assemble into a polymer matrix.
- an initiator may be used to crosslink the polymers.
- changes in pH, temperature, or ion concentration initiate spontaneous assembly of the polymer matrix.
- polyethylene glycols PEGs
- polysaccharides poly(lactic acids); polyurethanes; poly(propylene glycols); poly(propylene fumarate-co-ethylene glycol); poly(hydroxyethyl methacrylate); polyvinylpyrrolidones; poly(2-acrylamido-2-methyl-1-propanesulfonic acid); polyvinyl alcohols; polypeptides; polyacrylates; agaroses; poly(hydroxyethylmethacrylates); polyesters; gelatins; celluloses; alginates; k-carrageenans; pectins; starches; dextrans; chondroitin sulfates; and certain proteins such as collagen
- the liquid pre-polymer composition comprises a polymer chosen from polyethylene glycols, chitosans, hyaluronic acids, and combinations thereof.
- the specific polymers, mixture of polymers, and relative amount of polymers may be chosen to result in a polymer matrix or scaffold that is hydrophilic and biodegradable.
- the polymer matrix is produced from PEG or combinations of PEG alone, such as poly(ethylene glycol) diacrylate of molecular weight 1000 or poly(ethylene glycol) diacrylate of molecular weight 4000 or combinations thereof.
- the polymer matrix is produced from methacrylated chitosan alone, methacrylated hyaluronic acid alone, methacrylated chitosan and methacrylated hyaluronic acid together, methacrylated chitosan and hyaluronic acid together, or PEG in combination with methacrylated chitosan, methacrylated hyaluronic acid, hyaluronic acid or combinations thereof.
- the polymers may be chemically modified, or purchased as a chemically modified version. In some embodiments, the polymers are chemically modified (or purchased as a chemically modified version) for one or more of the following reasons: to permit or facilitate the formation of the polymer matrix, to improve gelation, cell adhesion, drug release, protein adhesion, degradation rate and profile, drug loading/incorporation, surface properties, mechanical properties, hydrophilicity, etc.
- the polymers may be functionalized with groups that cells can bind to such as cell-binding domains of amino acids, ligands, proteins, or other molecules intended to improve cell and protein adhesion to the scaffold.
- the amino acid sequence arginine-glycine-aspartic acid-serine (RGDS) may be incorporated into a PEG to increase cell adhesion.
- the molecular weight of the polyethylene glycol (PEG) may range from about 100 to about 1,000,000 g/mol. In some embodiments, the molecular weight of the chitosan may range from about 100 to about 1,000,000 g/mol, with deacylation ranging from about Oto about 100%. In some embodiments, the molecular weight of the hyaluronic acid may range from about 100 to about 1,000,000 g/mol. In certain embodiments, any of the ranges above may be incorporated in a hydrogel in some manner. In some embodiments, the chitosan used for the polymer matrix or scaffold may be either purchased or acquired from shellfish.
- Chitosan is a suitable polymer alone or in combination with other polymers because it is derived from naturally occurring sources and can be modified such that it is capable of crosslinking into a polymer matrix. When crosslinked it is tacky and sticks to epithelial cell surfaces. Cells are able to grow through and degrade a chitosan network. Due to the functional groups on the polysaccharide backbone of chitosan, it can be used as an antibacterial agent. Though chitosan is derived from chitin found in shellfish, it does not possess any of the allergy-inducing characteristics.
- Hyaluronic acid is also a suitable polymer alone or in combination with other polymers because is it also derived from naturally-occurring sources. It is used in many medical applications, as its functional groups make it an excellent substrate for cell growth. Hyaluronic acid can also be modified to be able to crosslink into a polymer matrix.
- PEG e.g. PEG diacrylate
- PEG is a suitable polymer alone or in combination with other polymers because it is available in a variety of molecular weights, from relatively short polymer chains to relatively long polymer chains, facilitating control of the degradation and drug release rates of the resulting polymer matrix.
- PEG is used in combination with other polymers such as chitosan or hyaluronic acid in order to result in a scaffold to which cells can adhere.
- polymers listed above may also be used/modified in place of chitosan, hyaluronic acid and/or PEG.
- suitable polymers include mechanical properties, drug release, polymer degradation, and cell growth and viability.
- mechanical properties this parameter depends on the polymer backbone and crosslink density.
- a person of skill can balance polymer concentration, initiator concentration, irradiation time, and output to obtain a crosslinked gel with a desired stiffness.
- the mechanical properties of the material influence the release of drugs from the material, with release rate being related to the pore size of the material.
- release rate is related to the pore size of the material.
- polymer degradation this parameter depends on the structure of the polymer, polymer concentration and environmental factors, such as cells and enzymes. Both chitosan and hyaluronic acid (as well as PEG) are able to be degraded by cells and enzymes found in the tympanic membrane environment. With respect to cell growth and viability, this depends on the functional groups of the polymer backbone and the stiffness of the polymer matrix. Epithelial cells are thought to prefer stiff substrates, accordingly in some embodiments the polymer or polymer blend is chosen to yield a stiff gel.
- a stiff gel is a gel with a higher elastic modulus than its pre-polymerized form. In some embodiments, a stiff gel is one that is sufficiently stiff that when positioned to cover a perforation it won't fall through the perforation into the middle ear. Additionally, chitosan and hyaluronic acid may provide functional groups to allow cells to adhere to the polymer network.
- the liquid pre-polymer composition may also include an initiator if required to initiate assembly of the polymers into a polymer matrix.
- an initiator if required to initiate assembly of the polymers into a polymer matrix.
- the initiator may be non-carcinogenic and non-cytotoxic.
- the initiators may include systems that are cytocompatible, light-sensitive, free radical initiators often used to cure/assemble methacrylate- and acrylate-containing polymer gels.
- the composition may include a photoinitiator if applicable to cause crosslinking of the polymers in solution.
- the photoinitiator system may be used to initiate a free-radical reaction to induce gelation of the scaffold, with the light having a wavelength ranging from about 10-8 to about 10-3 m (ultraviolet through infrared).
- a photoinitiator that is activated within the visible light spectrum may be chosen.
- a photoinitiator that is activated by UV light or blue light may be chosen.
- Suitable photoinitiators include Irgacure 2959 if curing or activating with UV light-sensitive compounds, eosin Yin conjunction with 1-vinyl-2 pyrrolidinone and trithanolamine if curing or activating with visible light-sensitive compounds, and camphorquinone and/or riboflavin 5′-monophosphate sodium salt if curing or activating with blue light.
- the forming polymer matrix/scaffold/hydrogel is designed to remain translucent as it polymerizes to facilitate light permeating the entire depth of the forming matrix/scaffold/gel and liquid pre-polymer solution.
- the liquid polymer composition of the scaffold may be loaded (at least partially) with drugs or other substances, (e.g., antibiotics, antimicrobials, growth factors, antifungals, anti-inflammatories, analgesics, steroids, cytokines, proteins, pain relievers and biologically active small molecules, etc.) prior to curing or activating with light into a gel or solid.
- drugs or other substances e.g., antibiotics, antimicrobials, growth factors, antifungals, anti-inflammatories, analgesics, steroids, cytokines, proteins, pain relievers and biologically active small molecules, etc.
- antibiotics such as fluoroquinolones, aminoglycosides, and polymixins.
- antifungal agents such as clotrimazole, nystatin, and tolnaftate.
- the scaffold may be loaded with growth factors, such as fibroblast growth factors, vascular endothelial growth factors, transforming growth factors, epidermal growth factors, keratinocyte growth factors, platelet-derived growth factors.
- the scaffold may be loaded with other molecules, such as interleukins and additional protein treatment or other curing treatment.
- the scaffold may be in the form of a hydrogel.
- hydrogels are hydrophilic polymer networks having a water content higher than about 90%, providing the hydrogels with an enhanced ability to encapsulate cells, bioactives and drug molecules as compared to materials that are not hydrogels.
- a person of skill understands how to load a drug into a polymer network, for example by mixing the drug with the pre-polymerization solution resulting later in the drug being confined to the pores of the polymer network upon assembly. See, e.g., Bhattarai, N. et al. Adv. Drug Deliv. Rev. (2010) 62:83-89, and Han, J. et al. Int. J. Biol. Macromol. (2009) 44:229-235. It is also within the skill of the art to create a system with a desired controlled drug release profile. The release of the drug relates to the pore size of the scaffold as well as the degradation rate of the scaffold. See, e.g., id.
- the concentration of polymer in solution may be changed, as well as the number of crosslinking sites on the polymer backbone. Altering these parameters changes the crosslinking density of the polymer network, and effectively the pore size.
- the scaffold also has a measurable stiffness associated with the polymer backbone, crosslink density, polymer concentration and initiator concentration.
- the liquid pre-polymer compositions therefore comprise at least a first polymer (which is capable of selectively assembling into a polymer matrix under defined conditions in the ear of a patient) and a solvent.
- the liquid pre-polymer compositions comprise at least a first polymer, an initiator and a solvent.
- the liquid pre-polymer compositions comprise at least a first polymer and at least a second polymer and a solvent.
- the liquid pre-polymer compositions comprise at least a first polymer and at least a second polymer, an initiator and a solvent.
- the amount of polymer is chosen to result in a desired viscosity for the pre-polymerization solution (for example a viscosity compatible with the pre-polymerization solution being able to cover a perforation and not fall through the perforation into the middle ear) and a desired stiffness for the resulting polymer matrix/scaffold/hydrogel after polymerization (for example a stiffness compatible with the material functioning as a scaffold after assembling).
- the amount (concentration) of initiator may be chosen based upon irradiation time required for polymerization, wavelength of light source, cell compatibility, and chemical composition.
- the total amount of polymer is not so high as to impede or prevent the polymers from assembling into a network and not so low such that the amount of polymer is insufficient to allow network assembly.
- the total amount of polymer is chosen to result in a viscous solution rather than a heterogenous paste, which may vary depending upon the specific polymer composition.
- the total amount of polymer is about 60 wt % or less (for example when polyhydroxylethylmethacrylate (PHEMA) is used), or about 40 wt % or less (for example when PEG is used), or about 5 wt % or less (for example for some combinations of chitosan/hyaluronic acid).
- the total amount of polymer is greater than about 1 wt %. In some embodiments, the total amount of polymer ranges from about 1 wt % to about 60 wt %, or about 1 wt % to about 40 wt %, or from about 1 wt % to about 5 wt %, or from about 5 wt % to about 60 wt % or from about 5 wt % to about 40 wt %, or from about 40 wt % to about 60 wt %.
- the methods include administering liquid pre-polymer compositions to a desired site in a patient's ear and curing/assembling the compositions in vivo.
- a syringe may be used for delivering the pre-polymerization solution down the narrow ear canal.
- the pre-polymerization solution may be applied to a surgical tool such as an ear loop and then administered to the tympanic membrane.
- the administration may vary depending on the mode of polymer assembly.
- the pre-polymerization solutions are irradiated after placement, for example with a dental during light or any other light source that provides the correct wavelength and intensity specific to the photoinitiator used (e.g. a UV or blue light sensitive gel).
- Heat sensitive networks may be activated, in some embodiments, by the patient's body temperature upon placement in the ear cavity.
- pH sensitive gels may be activated, in some embodiments, by the acidic environment in the ear canal following placement.
- Spontaneously assembling networks may be injected, in some embodiments, via a double-lumen syringe so that the polymer and its initiator are mixed as they are placed at the desired site, for example within the perforation.
- the methods include enhancing existing otologic treatment methods, such as otologic packing materials or patches.
- the pre-polymerized solution may be applied to other surgical materials to enhance their effect such as by providing a drug-delivering modality to packing materials.
- the pre-polymerized solution may be applied to surgical materials to enhance their adhesive character to the native tissue.
- precursors may comprise poly(ethylene glycol) diacrylate of molecular weight 1000 or poly(ethylene glycol) diacrylate of molecular weight 4000 purchased from Polysciences Inc. (Warrington, Pa.).
- Albumin from bovine serum (BSA), tetramethylrhodamine conjugate may be purchased from Invitrogen Inc. (Eugene, Oreg.).
- Drug incorporation and release were tested.
- Hydrogels were loaded with BSA during the initial crosslinking procedure. A 10% w/v solution of BSA in PBS with pH 7.4 was prepared. Photocrosslinkable solutions of 10% w/v PEG in PBS with 0.5% Irgacure 2959 photoinitiator were prepared.
- BSA was incorporated into the solutions at 5 wt % to macromer loading. The final solutions were stirred for 15 minutes at 350 rpm. Then 200 ⁇ L was pipetted into wells of a 96 well plate. Each construct was irradiated with UV light for 55 sec. The gels were immediately removed from the wells using a spatula and placed in separate vials containing 5 ml of PBS solution. Then the vials were placed in a shaker at 37° C. (50 rpm). At different time points 500 ⁇ L of the PBS solution was removed as a sample and replaced with the same amount of PBS. A Hewlett Packard Diode Array Spectrophotometer (model 8452A) was used to evaluate amount of BSA that was released at each time point.
- one embodiment of the present invention may comprise the following administration.
- the patient may be lying down on their side, with their ear under a microscope. This allows the physician to view and work with the tympanic membrane with both hands free.
- the physician is now able to administer the liquid pre-polymer composition that has been mixed with the desired drugs.
- the composition can be dropped into the ear with a pipette, much like eardrops are administered. It is likely that the physician will only need tens of microliters of composition to cover the perforation. Once the composition has been added and covers the perforation, the physician can then irradiate the composition with light wherever a hydrogel is needed.
- excess composition may be removed with either a pipette or some absorbent object according to the physician's preference. Any excess of composition can be added to ensure that the perforation is covered by the gel, since all excess composition can be removed.
- An attachment for the light source (such as a fiber optic cable) may be used to reach the TM of all patients. Since this all takes place under a microscope, the physician is able to be precise in covering the perforation with gel.
- one embodiment of the present invention may comprise enhancing current surgical packing materials for the middle ear.
- the liquid pre-polymer composition that has been mixed with the desired drugs may be dropped onto the packing material and polymerized with light prior to closing the surgical wound.
- This embodiment would afford the surgical packing material some antibacterial and drug delivery characteristics that it does not currently possess, in addition to enhanced mechanical support, thus improving the post-surgery prognosis.
- FIG. 1 illustrates the histogram of bovine serum albumin released from PEG hydrogels of two different molecular weights over time.
- the pore size of the hydrogel network may also increase. This may result in a larger volume of the drug being released over time. Additionally, the degradation rate of the hydrogel may increase. In some embodiments, it may be desirable to optimize both the release rate of the drug, and the degradation rate of the hydrogel network.
- the degradation rate may increase when the scaffold is in the presence of cells actively remodeling their environment, such as the tympanic membrane.
- the degradation rate of the scaffold may change when in other tissues because of a difference in pH or native molecules that either speed up or slow down the degradation rate. For example, a change in degradation rate would probably be most obvious in the digestive tract, where the pH is very different from normal body fluid, and many different molecules for degrading different scaffolds are present. As a counter-example, the degradation rate probably will not change in the vitreous of the eye.
- Chitosan was purified before use. First, a 1 wt % solution of chitosan in 10 vol % acetic acid was vacuum-filtered to remove insoluble particles. Next, the chitosan was precipitated from solution with 1N sodium hydroxide, then centrifuged at 1400 g for 10 min at room temperature. The supernatant was decanted, then water was added in equal volume to the chitosan and the mixture vortexed. The chitosan suspension was dialyzed in water for 2 d, with water changes 3 times/day. After dialysis, the chitosan suspension was lyophilized for 3 d.
- chitosan was dissolved in 1 vol % acetic acid. A volume of methacrylic anhydride equal to 5% of the volume of 1% acetic acid was added to the chitosan solution, and the solution was stirred for 3 d at 55° C. The chitosan solution was dialyzed in water for 2 d with water changes 3 times/day. The dialyzed solution was lyophilized for 3 d.
- the degree of methacrylation of methacrylated chitosan was determined by proton nuclear magnetic resonance spectroscopy, and determined to be ⁇ 40%.
- the solvent system was the main variable to overcome, as neither CQ nor EDMAB are water-soluble.
- Riboflavin monophosphate is a water-soluble version of the vitamin riboflavin. It is also a blue-light photoinitiator that has recently been used to polymerize methacrylated long-chain polymers.
- the pre-polymerized solution was irradiated for 3 min using a custom light guide (Leoni, Nuremburg, Germany) fitted to a dental curing light (Mini-Blast, First Medica, Greensboro, N.C.) with a power output of 300 mW/cm 2 ⁇
- the release of ciprofloxacin was dependent upon the polymer network crosslinking density of the material.
- FIG. 2 the release of ciprofloxacin is compared between gels consisting of either 2 wt % MeCS or 2 wt % MeCS/1 wt % HA. Because the gel with both MeCS and HA has a higher crosslink density than the gel with only MeCS, the release of ciprofloxacin was significantly slower.
- FIG. 3 shows the cumulative release of ciprofloxacin over the course of the study. A slower release profile may be advantageous for the material, as it may extend the time window the perforation has to heal without risk of infection. Neither material demonstrated a “burst release” profile—a sudden release of drugs incongruous with the rest of the release profile—confirming that the release of ciprofloxacin can be controlled by crosslink density.
- the pre-polymerized solution of MeCS, HA, riboflavin monophosphate, and ciprofloxacin were mixed in water and loaded into a syringe.
- the viscous solution was then ejected onto an ear loop and transferred to the perforation.
- the material was cured using a dental curing light with the custom light guide.
- the gel patch was initially applied to 2 perforations, with 1 perforation used as a control.
- the gel-patched perforations were monitored weekly, and the healing rate compared to perforations not patched with the material.
- the gel patch adhered to the perforation site, and was present 3 weeks after implantation. There was evidence of cell ingrowth within the gel, and there has been no incidence of infection or adverse reaction in animals that received the gel patch. The perforation healed four weeks after the gel application. The study suggests that the material may require four weeks to repair chronic perforations in the TM. The perforation that did not receive the gel patch was still persistent.
Abstract
Otologic materials and methods are provided. For example, a cell-adhesive, biodegradable hydrogel scaffold loaded with time-released drugs for repairing chronic tympanic membrane perforations is disclosed, methods of making same and administering same are provided. This hydrogel may promote vascular in-growth and epithelial cell growth of the tympanic membrane with the purpose of closing the perforation and providing a barrier between the external and middle ear. The hydrogel is initially a liquid polymer that only gels upon exposure to specific conditions, such as exposure to light. This scaffold may simultaneously induce repair of the tympanic membrane while preventing or alleviating middle ear infection, thus filling a void in current tympanic membrane perforation therapies.
Description
- This application is a continuation of U.S. patent application Ser. No. 16/449,430, entitled “Selectively Polymerizable Compositions and Methods of Use In Vivo,” filed Jun. 23, 2019, which is a divisional of U.S. patent application Ser. No. 14/583,708, entitled “SELECTIVELY POLYMERIZABLE COMPOSITIONS AND METHODS OF USE IN VIVO”, filed Dec. 28, 2014, which application is a continuation of International Application No. PCT/US2013/048385, filed Jun. 28, 2013, which claims benefit of priority to U.S. Provisional Patent Application No. 61/665,639, entitled, “SELECTIVELY POLYMERIZABLE HYDROGEL FOR USE AS A MULTI-PURPOSE SURGICAL SCAFFOLD WITH DRUG-DELIVERY CAPABILITIES,” filed Jun. 28, 2012. The foregoing utility applications, PCT application, and provisional application are hereby incorporated by reference in their entirety.
- In the US alone, over 1,000,000 procedures to insert pressure equalizing tubes (PETs) in the tympanic membrane (TM) are performed each year. These tubes allow fluid from middle ear infections to drain from the middle ear to the external ear canal, thus relieving the pain from pressure build-up. Chronic TM perforations are generally thought to occur when PETs are left in the TM for extended periods of time. For PETs left in the TM for 18 months or less, the chronic TM perforation rate is between 1-5%. However, some patients require PETs for 2 years or longer—the rate of chronic TM perforation for this group is about 9%.
- To treat chronic TM perforations, the fibrous tissue around the perforation is abraded to induce an inflammatory response. If the perforation is small such as about 20% or less of the cross-sectional area of the TM, the perforation can be packed with either paper or fat taken from the earlobe. Larger perforations require a more substantial packing material, such as autografts of cartilage or fascia, surgical gelatin, or a synthetic polymer patch. All of these therapies require some kind of surgery, and the success rate of the therapy is highly dependent upon the skill of the surgeon.
- There are several commercial otologic packing products available in the market. Pfizer manufactures Gelfoam®, a type of surgical gelatin obtained from pigs used as a packing material for the middle ear after surgery. Typically, once the middle ear has been cleared of fluid via surgery, Gelfoam® is used to fill the void in the middle ear. Gelfoam® liquefies when hydrated, and is degraded and cleared easily by the body. In addition to acting as a barrier between the middle and external ear while the TM perforation heals, it also provides a surface to which autografts or patches may adhere. However, due to the nature of porcine gelatin, some patients may be allergic to this material.
- Medtronic ENT/Xomed manufactures Merogel®, a fibrous packing material similar to that of Gelfoam®, but is instead made of hyaluronic acid. Merogel® turns into a gel when hydrated, and is easily degraded. It has the same properties as Gelfoam®, but without the risk of allergic reaction due to porcine gelatin. Like Gelfoam®, it is used to pack the middle ear prior to insertion of an autograft or patch, and is not used as a stand-alone treatment.
- Medtronic ENT/Xomed also manufactures EpiOisc™, a porous hyaluronic patch intended to repair tympanic membranes. It is biodegradable and induces both epithelial cell growth and vascular in-growth of the tympanic membrane. However, to use this patch, it must be trimmed to the size of the perforation and inserted surgically. Occasionally, the patch fails to adhere completely to the native tissue or packing material in the middle ear, resulting in additional surgery to replace the patch.
- None of the current products available for repairing TM-perforation deliver drugs directly to the middle ear. The current method for delivering drugs directly to the middle ear is with eardrops. The main drug used for treating ear infections (ciprodex) stings when applied. This is an important factor to consider when the majority of the patients treated for ear infections are children under the age of 10.
- To date, no photopolymerizable hydrogels have been used as scaffolds for otologic use, in which the liquid polymer is applied to the desired site prior to curing. Blue light-polymerizable materials are used in the dental field, but none of the components apply to otologic use. Using a scaffold that is initially a liquid and only forms a scaffold upon exposure to specific conditions is a total departure from current and traditional therapies for repairing TM perforations.
- While certain novel features of this invention shown and described below are pointed out in the claims, the invention is not intended to be limited to the details specified, since a person of ordinary skill in the relevant art will understand that various omissions, modifications, substitutions and changes in the forms and details of the invention illustrated and in its operation may be made without departing in any way from the spirit of the present invention. No feature of the invention is critical or essential unless it is expressly stated as being “critical” or “essential.”
- The present invention provides selectively polymerizable materials and methods of use in vivo. For example, the present invention provides selectively polymerizable otologic materials and methods of use of the materials in the ear of a patient.
- In some embodiments, the otologic materials are a liquid pre-polymer composition comprising at least a first polymer (capable of selectively curing/selectively assembling into a polymer matrix under defined conditions in the ear of a patient) and a solvent. In some embodiments, the otologic materials are a liquid pre-polymer composition comprising at least a first polymer, a solvent and an initiator which when activated in situ in the ear of a patient, results in the repairing or aiding in the repair of a tympanic membrane perforation. In further embodiments, the liquid pre-polymer composition also comprises a therapeutic composition. In some further embodiments, the polymer matrix has a porosity and an average pore size compatible with releasing the therapeutic composition over a desired time period. In some embodiments the polymer matrix may be in the form of a gel such as a hydrogel, and may have a stiffness sufficient to function as a scaffold on which epithelial cells of the tympanic membrane can migrate, adhere and grow. In some embodiments, the at least first polymer is functionalized such that the resulting polymer matrix has a cell-binding domain, for example, which may improve cell migration and adhesion. In some embodiments, the initiator is a photoinitiator which is activated by light, for example visible, ultraviolet, infrared, or blue light. In some embodiments, the at least first polymer is chosen from polyethylene glycols (PEGs) and polysaccharides such as methacrylated chitosan, hyaluronic acid and methacrylated hyaluronic acid. In further embodiments, the at least first polymer is one or more PEGs. In other embodiments, the at least first polymer is a methacrylated chitosan and hyaluronic acid. In alternative embodiments, the at least first polymer is a methacrylated chitosan and a methacrylated hyalauric acid. In yet other embodiments, the at least first polymer is a PEG in combination with at least one of a chitosan or a hyaluronic acid.
- Some embodiments of materials according to this disclosure, for example some embodiments of photo-curable hydrogel materials according to this disclosure, compare to certain commercial otologic products as shown in Table 1 below:
-
TABLE Surgery Drug Product Material Function required? delivery? GelFoam ® Porcine Packing Yes No (Pfizer) gelatin MeroGel ® Hyaluronic Packing Yes No (Medtronic) acid EpiDisc ™ Hyaluronic Patch Yes No (Medtronic) acid An exemplary Polyethylene Patch No Yes embodiment of the glycol/chitosan/ present invention hyaluronic acid - In some embodiments, the otologic methods include treating a perforation of the tympanic membrane by administering a liquid pre-polymer composition comprising at least a first polymer, a solvent and optionally an initiator (for example if required to activate the assembly of the at least first polymer into a polymer matrix) to the site of the perforation, and activating the composition (for example activating the initiator) resulting in the liquid composition assembling into a polymer matrix, such as a hydrogel. In further embodiments, the liquid composition also includes a therapeutic composition. In some embodiments, the method involves administering a sufficient amount of the liquid composition to at least cover the perforation. In some embodiments, wherein the composition comprises a photoinitiator, activating involves exposing the liquid composition to light such as blue light, visible light, infrared (IR) light or ultraviolet (UV) light. In some embodiments, activating involves exposing the composition to a change of temperature or a change of pH or a change of ion concentration for example such as may be found in the natural environment of the ear. In some embodiments, activating involves exposing the liquid composition to chemical radical initiators. Other methods of activating the liquid compositions are also within scope of this disclosure provided they are biocompatible and suitable for the specific purpose, such as use in repairing perforations of tympanic membranes, or such as timed release delivery of drugs in the ear.
- In some embodiments, the otologic methods involve enhancing existing otologic packing materials by administering liquid pre-polymer compositions described herein to the packing materials and curing or assembling the liquid pre-polymer compositions after administration. In some embodiments, the otologic packing materials are first administered to a desired site in a patient's ear prior to administering the liquid pre-polymer compositions.
- The methods and materials may accomplish one or more of the following objects:
-
- Aid in the repair of chronic TM perforations of variable size, for example by providing a scaffold for new cell growth and releasing drugs in a time-dependent manner. The scaffold may be biodegradable, hydrophilic, non-carcinogenic, non-cytotoxic, non-ototoxic, and polymerizes only when exposed to a specific set of conditions, such as blue light, UV light, IR light or visible light, chemical radical initiators, or specific conditions of pH, ion concentration, temperature.
- Resolve some of the issues with current TM perforation therapies, including adherence of the scaffold to the surrounding tissue, and direct delivery of drugs to the middle ear to prevent recurring infection.
- Fill the area of a perforation in a tympanic membrane without the need for autografts or patches cut to the exact dimensions of the perforation, for example by delivering the scaffold in curable liquid form to the site of perforation. Such an approach may have the advantage of removing the skill of the surgeon as a factor for success rate of the procedure, for example because the compositions are configured to be viscous enough not to fall through the perforation into the middle ear.
- Forming a hydrogel scaffold stiff enough to retain its shape, adhesive enough to provide a scaffold on which epithelial cells of the TM can migrate and grow, and/or remain in the place it was assembled (for example due to is stiffness and adhesive properties). Drugs loaded into the liquid polymer may be confined to the pores of the scaffold upon assembly, for example with light, and are released as the cells of the TM degrade the crosslinks of the scaffold.
- Curing or assembling the scaffold using a photoinitiator or based on ionic strength, or using chemical catalysts or chemical groups that recognize each other and bind together, such as “click” reagents.
- Deliver drugs directly to the middle ear in order to prevent or alleviate a recurrent infection. For example, the materials and methods may result in releasing drugs in a controlled and sustained manner for a predetermined length of time. For example, the dosage of the drug may be controlled by the degradation rate of the scaffold and the amount loaded into the liquid polymer. Such an approach may have an advantage over eardrops, which can only release drugs to the TM and middle ear in a single burst, thus requiring timed reapplication over the course of the treatment. Such an approach may also provide a more efficient method for delivering more exact quantities of drug to the middle ear over current therapies. Such an approach may also enhance the effect of the drugs as compared to current therapies.
- Deliver drugs directly to the middle ear of patients, and for example children, to allow easier administration of otological treatments.
- Deliver drugs to the vitreous.
- Provide physicians an option to use a selectively-polymerizable scaffold for sustained drug release, for example where such an approach may be beneficial, whether in a clinical or surgical setting.
- Enhance the features of existing products and treatments by using the materials and methods in accordance with this disclosure in conjunction with one or more of existing treatments.
- Form a scaffold such as by using one or more of polyethylene glycol (PEG), chitosan, hyaluronic acid, and/or analogs or derivatives thereof as a scaffold.
- Form a functionalized scaffold with a cell-binding domain, for example to improve cell adhesion and migration on the scaffold.
- Design a target drug time release profile for the polymer matrix, for example through use of a particular amount of PEG.
- While the disclosure provides certain specific embodiments, the invention is not limited to those embodiments. A person of ordinary skill will appreciate from the description herein that modifications can be made to the described embodiments and therefore that specification is broader in scope than the described embodiments. All examples are therefore non-limiting.
-
FIG. 1 is a graph illustrating a quantification of bovine serum albumin released from exemplary PEG hydrogels of two different molecular weights over time. -
FIG. 2 is a graph illustrating Ciprofloxacin release from 2% MeCS and 2% MeCS/1% HA in 0.5% lysozyme in water. -
FIG. 3 is a graph illustrating Cumulative release of ciprofloxacin from 2% MeCS and 2% MeCS/1% HA in 0.5% lysozyme in water. - Detailed descriptions of one or more embodiments are provided herein. It is to be understood, however, that the present invention may be embodied in various forms. Therefore, specific details disclosed herein are not to be interpreted as limiting.
- Where ever the phrase “for example,” “such as,” “including” and the like are used herein, the phrase “and without limitation” is understood to follow unless explicitly stated otherwise. Similarly “an example,” “exemplary” and the like are understood to be non-limiting.
- The term “substantially” allows for deviations from the descriptor that don't negatively impact the intended purpose. Descriptive terms are understood to be modified by the term “substantially” even if the word “substantially” is not explicitly recited. Therefore, for example, the phrase “an embodiment with
PEG MW 4000” means “an embodiment with substantiallyPEG MW 4000” so long as a precise molecular weight is not necessary for the embodiment to perform its function. - The term “about” is meant to account for variations due to experimental error. All measurements or numbers are implicitly understood to be modified by the word about, even if the measurement or number is not explicitly modified by the word “about.”
- The terms “comprising” and “including” and “having” and “involving” (and similarly “comprises”, “includes,” “has,” and “involves”) and the like are used interchangeably and have the same meaning. Specifically, each of the terms is defined consistent with the common United States patent law definition of “comprising” and is therefore interpreted to be an open term meaning “at least the following,” and is also interpreted not to exclude additional features, limitations, aspects, etc. Thus, for example, “a process involving steps a, b, and c” means that the process includes at least steps a, band c.
- Where ever the terms “a” or “an” are used, “one or more” is understood, unless such interpretation is nonsensical in context.
- The term “liquid pre-polymer composition” or alternatively “pre-polymerization solution” mean the same thing and refer to a composition (comprising at least one polymer) which is capable of being activated to assemble into a more viscous form but that has not yet so assembled. A “liquid pre-polymer composition” need not be liquid but only less viscous than its assembled form. In some embodiments, a “liquid pre-polymer composition” is sufficiently viscous such that it can be positioned to cover a perforation without falling through to the middle ear cavity.
- The terms “scaffold” refers to a “polymer matrix” having properties compatible with treating a perforation of the tympanic membrane such as by having a stiffness compatible with the migration and growth of epithelial cells on or in the scaffold, and/or by having a porosity compatible with releasing a therapeutic composition, which was part of the liquid pre-polymer composition for example according to a desired time-dependent profile.
- The terms “polymerization,” “gelation,” “crosslinking,” “assembling” and “curing” mean the transition of materials, such as otologic materials, according to this disclosure from a liquid pre-polymer to a harder or tougher form such as a gel, solid, or interpenetrating polymer network, which may result from activating the materials such as by adding an assembling agent or curing agent (and activating the agent by for example light, pH, body fluids, temperature, other chemical changes, etc.) or having the pre-polymer assemble or cure through existing natural conditions (for example activating the assembly of the polymers in the liquid pre-polymer composition into a polymer matrix due to the presence of body fluids or existing conditions for example of pH or temperature or ion concentration at the site of administration).
- Reference to a polymer, such as “chitosan,” “polyethylene glycol,” or “hyaluronic acid,” (as well as reference to those polymers in plural, such as “chitosans,” “polyethylene glycols,” and “hyaluronic acids”) is understood to be reference to a class of polymers, unless in context it is clear that only the basic (backbone) polymer is intended. In other words, the term “chitosan” means chitosan and its derivatives and analogs (for example methacrylated chitosan), the term “polyethylene glycol” refers to polyethylene glycol, its derivatives and analogs, and the term “hyaluronic acid” means hyaluronic acid, its derivatives and analogs.
- The present disclosure provides otologic materials and methods. In some embodiments, the otologic materials and methods are directed at treating perforations of the tympanic membrane (TM), including chronic perforations of the TM. In some embodiments, the otologic materials comprise a liquid pre-polymer composition that is cured/assembled in situ resulting in a polymer matrix, for example in the form of a hydrogel scaffold. In some further embodiments, the otologic materials are loaded with drugs, for example for direct delivery to the middle ear to prevent infection, for example recurring infection. In some embodiments, the methods comprise administering the otologic liquid pre-polymer materials to a desired site in a patient's ear and curing/assembling the materials in situ. In some embodiments, the methods comprise administering the liquid pre-polymer materials to an otologic packing material and curing/assembling the liquid pre-polymer materials after administration to the packing material.
- Materials
- Materials according to this disclosure include liquid pre-polymer compositions, which can be cured/assembled into a polymer matrix. The materials also include the resultant polymer matrix itself. In some embodiments, the polymer matrix is a scaffold having sufficient stiffness and/or tackiness (for example as a result of functional groups providing cell adhesion domains) such that epithelial cells in the TM can migrate into and/or onto the scaffold and adhere and/or grow. In some further embodiments, the polymer matrix or scaffold eventually degrades in situ, i.e. is biodegradable, for example after the epithelial cells have grown sufficiently to repair the perforation. In alternative or further embodiments, the liquid pre-polymer composition is designed to cure/assemble into a polymer matrix or scaffold having a porosity and average pore size compatible with loading the resultant polymer matrix or scaffold with a therapeutic agent. In additional embodiments, the porosity and average pore size are chosen to provide a desired time-dependent release profile for the loaded therapeutic agent.
- In general, the otologic materials according to this disclosure are initially a pre-polymer liquid composition for easy administration to a desired site in a patient's ear, and are configured to cure/assemble into a polymer matrix in vivo in the ear of a patient upon activation. Accordingly, in general, the liquid pre-polymer compositions include one or more polymers capable of selectively assembling into a polymer matrix at a desired time under specific conditions (for example conditions found in the ear, such as the middle ear), and a solvent. Thus, for example, the liquid pre-polymer composition may include an initiator, such as a photoinitiator, and the polymers in the liquid pre-polymer composition may be selectively assembled by exposing the composition to light thereby activating the initiator resulting in curing/assembling the pre-polymer composition into a polymer matrix. As one example, the polymers may be functionalized with methacrylate groups to give them cross-linkability, and riboflavin (a non-carcinogenic, non-cytotoxic photoinitiator) may be added to the liquid pre-polymer composition to initiate the cross-linking of the methacrylate groups in the presence of light. In general, the composition ingredients are chosen to be biocompatible and suitable for use in the ear, for example the external auditory canal, middle ear, or both. In some embodiments, the ingredients are chosen such that the resultant polymer matrix is biodegradable, and may be processed and cleared by the body. For example, the components chosen are biodegradable, biocompatible, and may be expelled by the kidneys.
- In some embodiments, the liquid pre-polymer composition includes at least a first polymer capable of assembling into a polymer matrix, e.g. capable of being cured/assembled such as capable of reacting under defined conditions to form a polymer matrix. For example, the polymer may include functional groups that can associate to form a network, for example through formation of covalent bonds, physical bonds, or combinations of both. Without wishing to be bound by theory, the functional groups on the polymer may determine how it can assemble into a polymer matrix. In some embodiments, for example where the polymer is functionalized with methacrylate groups (for example chitosan or hyaluronic acid), an initiator may be used to crosslink the polymers. In another embodiment, changes in pH, temperature, or ion concentration initiate spontaneous assembly of the polymer matrix.
- Examples of potentially suitable polymers include the following, and/or derivatives and analogs thereof (for example derivatives include polymers listed below which are modified to include functional groups that can associate to form a network, and/or for example the polymers listed below may be functionalized to achieve a desired goal such as providing cell adhesion domains): polyethylene glycols (PEGs); polysaccharides; poly(lactic acids); polyurethanes; poly(propylene glycols); poly(propylene fumarate-co-ethylene glycol); poly(hydroxyethyl methacrylate); polyvinylpyrrolidones; poly(2-acrylamido-2-methyl-1-propanesulfonic acid); polyvinyl alcohols; polypeptides; polyacrylates; agaroses; poly(hydroxyethylmethacrylates); polyesters; gelatins; celluloses; alginates; k-carrageenans; pectins; starches; dextrans; chondroitin sulfates; and certain proteins such as collagen, fibrin, laminin and heparin. In some embodiments such as embodiments wherein the polymer matrix may degrade, components are chosen to result in degradation products that are not ototoxic.
- In some embodiments, the liquid pre-polymer composition comprises a polymer chosen from polyethylene glycols, chitosans, hyaluronic acids, and combinations thereof. In some embodiments, the specific polymers, mixture of polymers, and relative amount of polymers may be chosen to result in a polymer matrix or scaffold that is hydrophilic and biodegradable. In some embodiments, the polymer matrix is produced from PEG or combinations of PEG alone, such as poly(ethylene glycol) diacrylate of molecular weight 1000 or poly(ethylene glycol) diacrylate of
molecular weight 4000 or combinations thereof. In some embodiments, the polymer matrix is produced from methacrylated chitosan alone, methacrylated hyaluronic acid alone, methacrylated chitosan and methacrylated hyaluronic acid together, methacrylated chitosan and hyaluronic acid together, or PEG in combination with methacrylated chitosan, methacrylated hyaluronic acid, hyaluronic acid or combinations thereof. - In some embodiments, the polymers may be chemically modified, or purchased as a chemically modified version. In some embodiments, the polymers are chemically modified (or purchased as a chemically modified version) for one or more of the following reasons: to permit or facilitate the formation of the polymer matrix, to improve gelation, cell adhesion, drug release, protein adhesion, degradation rate and profile, drug loading/incorporation, surface properties, mechanical properties, hydrophilicity, etc. For example, the polymers may be functionalized with groups that cells can bind to such as cell-binding domains of amino acids, ligands, proteins, or other molecules intended to improve cell and protein adhesion to the scaffold. As one example, the amino acid sequence arginine-glycine-aspartic acid-serine (RGDS) may be incorporated into a PEG to increase cell adhesion.
- In further embodiments, the molecular weight of the polyethylene glycol (PEG) may range from about 100 to about 1,000,000 g/mol. In some embodiments, the molecular weight of the chitosan may range from about 100 to about 1,000,000 g/mol, with deacylation ranging from about Oto about 100%. In some embodiments, the molecular weight of the hyaluronic acid may range from about 100 to about 1,000,000 g/mol. In certain embodiments, any of the ranges above may be incorporated in a hydrogel in some manner. In some embodiments, the chitosan used for the polymer matrix or scaffold may be either purchased or acquired from shellfish.
- Chitosan is a suitable polymer alone or in combination with other polymers because it is derived from naturally occurring sources and can be modified such that it is capable of crosslinking into a polymer matrix. When crosslinked it is tacky and sticks to epithelial cell surfaces. Cells are able to grow through and degrade a chitosan network. Due to the functional groups on the polysaccharide backbone of chitosan, it can be used as an antibacterial agent. Though chitosan is derived from chitin found in shellfish, it does not possess any of the allergy-inducing characteristics.
- Hyaluronic acid is also a suitable polymer alone or in combination with other polymers because is it also derived from naturally-occurring sources. It is used in many medical applications, as its functional groups make it an excellent substrate for cell growth. Hyaluronic acid can also be modified to be able to crosslink into a polymer matrix.
- PEG (e.g. PEG diacrylate) is a suitable polymer alone or in combination with other polymers because it is available in a variety of molecular weights, from relatively short polymer chains to relatively long polymer chains, facilitating control of the degradation and drug release rates of the resulting polymer matrix. In some embodiments, PEG is used in combination with other polymers such as chitosan or hyaluronic acid in order to result in a scaffold to which cells can adhere.
- However, other polymers listed above may also be used/modified in place of chitosan, hyaluronic acid and/or PEG. In general some factors to consider in choosing suitable polymers (derivatives and analogs thereof) include mechanical properties, drug release, polymer degradation, and cell growth and viability. With respect to mechanical properties, this parameter depends on the polymer backbone and crosslink density. For example, in the case of a hydrogel polymer matrix, formed by exposing the liquid solution to light, a person of skill can balance polymer concentration, initiator concentration, irradiation time, and output to obtain a crosslinked gel with a desired stiffness. With respect to drug release, the mechanical properties of the material influence the release of drugs from the material, with release rate being related to the pore size of the material. With respect to polymer degradation, this parameter depends on the structure of the polymer, polymer concentration and environmental factors, such as cells and enzymes. Both chitosan and hyaluronic acid (as well as PEG) are able to be degraded by cells and enzymes found in the tympanic membrane environment. With respect to cell growth and viability, this depends on the functional groups of the polymer backbone and the stiffness of the polymer matrix. Epithelial cells are thought to prefer stiff substrates, accordingly in some embodiments the polymer or polymer blend is chosen to yield a stiff gel. In some embodiments, a stiff gel is a gel with a higher elastic modulus than its pre-polymerized form. In some embodiments, a stiff gel is one that is sufficiently stiff that when positioned to cover a perforation it won't fall through the perforation into the middle ear. Additionally, chitosan and hyaluronic acid may provide functional groups to allow cells to adhere to the polymer network.
- The liquid pre-polymer composition may also include an initiator if required to initiate assembly of the polymers into a polymer matrix. In some embodiments, it is desirable for the initiator to be non-carcinogenic and non-cytotoxic. In some embodiments, the initiators may include systems that are cytocompatible, light-sensitive, free radical initiators often used to cure/assemble methacrylate- and acrylate-containing polymer gels. For example, the composition may include a photoinitiator if applicable to cause crosslinking of the polymers in solution. For example, the photoinitiator system may be used to initiate a free-radical reaction to induce gelation of the scaffold, with the light having a wavelength ranging from about 10-8 to about 10-3 m (ultraviolet through infrared). In some embodiments, for example those used in the vitreous, a photoinitiator that is activated within the visible light spectrum may be chosen. In other embodiments, such as embodiments for otologic purposes, a photoinitiator that is activated by UV light or blue light may be chosen. Some examples of suitable photoinitiators include Irgacure 2959 if curing or activating with UV light-sensitive compounds, eosin Yin conjunction with 1-vinyl-2 pyrrolidinone and treithanolamine if curing or activating with visible light-sensitive compounds, and camphorquinone and/or
riboflavin 5′-monophosphate sodium salt if curing or activating with blue light. In some embodiments, the forming polymer matrix/scaffold/hydrogel is designed to remain translucent as it polymerizes to facilitate light permeating the entire depth of the forming matrix/scaffold/gel and liquid pre-polymer solution. - In some embodiments, the liquid polymer composition of the scaffold may be loaded (at least partially) with drugs or other substances, (e.g., antibiotics, antimicrobials, growth factors, antifungals, anti-inflammatories, analgesics, steroids, cytokines, proteins, pain relievers and biologically active small molecules, etc.) prior to curing or activating with light into a gel or solid. The scaffold may be loaded with antibiotics such as fluoroquinolones, aminoglycosides, and polymixins. The scaffold may be loaded with antifungal agents such as clotrimazole, nystatin, and tolnaftate. The scaffold may be loaded with growth factors, such as fibroblast growth factors, vascular endothelial growth factors, transforming growth factors, epidermal growth factors, keratinocyte growth factors, platelet-derived growth factors. The scaffold may be loaded with other molecules, such as interleukins and additional protein treatment or other curing treatment. To achieve this purpose of loading a scaffold/use of a scaffold for drug delivery, the scaffold may be in the form of a hydrogel. In some embodiments, hydrogels are hydrophilic polymer networks having a water content higher than about 90%, providing the hydrogels with an enhanced ability to encapsulate cells, bioactives and drug molecules as compared to materials that are not hydrogels.
- A person of skill understands how to load a drug into a polymer network, for example by mixing the drug with the pre-polymerization solution resulting later in the drug being confined to the pores of the polymer network upon assembly. See, e.g., Bhattarai, N. et al. Adv. Drug Deliv. Rev. (2010) 62:83-89, and Han, J. et al. Int. J. Biol. Macromol. (2009) 44:229-235. It is also within the skill of the art to create a system with a desired controlled drug release profile. The release of the drug relates to the pore size of the scaffold as well as the degradation rate of the scaffold. See, e.g., id. To change the pore size of the scaffold, for example, the concentration of polymer in solution may be changed, as well as the number of crosslinking sites on the polymer backbone. Altering these parameters changes the crosslinking density of the polymer network, and effectively the pore size. The scaffold also has a measurable stiffness associated with the polymer backbone, crosslink density, polymer concentration and initiator concentration.
- In some embodiments, the liquid pre-polymer compositions therefore comprise at least a first polymer (which is capable of selectively assembling into a polymer matrix under defined conditions in the ear of a patient) and a solvent. In further embodiments, the liquid pre-polymer compositions comprise at least a first polymer, an initiator and a solvent. In some embodiments, the liquid pre-polymer compositions comprise at least a first polymer and at least a second polymer and a solvent. In some embodiments, the liquid pre-polymer compositions comprise at least a first polymer and at least a second polymer, an initiator and a solvent. In some embodiments, the amount of polymer is chosen to result in a desired viscosity for the pre-polymerization solution (for example a viscosity compatible with the pre-polymerization solution being able to cover a perforation and not fall through the perforation into the middle ear) and a desired stiffness for the resulting polymer matrix/scaffold/hydrogel after polymerization (for example a stiffness compatible with the material functioning as a scaffold after assembling). In some embodiments, the amount (concentration) of initiator may be chosen based upon irradiation time required for polymerization, wavelength of light source, cell compatibility, and chemical composition. In some embodiments, the total amount of polymer is not so high as to impede or prevent the polymers from assembling into a network and not so low such that the amount of polymer is insufficient to allow network assembly. In some embodiments, the total amount of polymer is chosen to result in a viscous solution rather than a heterogenous paste, which may vary depending upon the specific polymer composition. In some embodiments, the total amount of polymer is about 60 wt % or less (for example when polyhydroxylethylmethacrylate (PHEMA) is used), or about 40 wt % or less (for example when PEG is used), or about 5 wt % or less (for example for some combinations of chitosan/hyaluronic acid). In some embodiments, the total amount of polymer is greater than about 1 wt %. In some embodiments, the total amount of polymer ranges from about 1 wt % to about 60 wt %, or about 1 wt % to about 40 wt %, or from about 1 wt % to about 5 wt %, or from about 5 wt % to about 60 wt % or from about 5 wt % to about 40 wt %, or from about 40 wt % to about 60 wt %.
- In some embodiments, the methods include administering liquid pre-polymer compositions to a desired site in a patient's ear and curing/assembling the compositions in vivo. For example, to administer the compositions to the tympanic membrane, a syringe may be used for delivering the pre-polymerization solution down the narrow ear canal. Alternatively, in some embodiments wherein the pre-polymerization solution is relatively very viscous, it may be applied to a surgical tool such as an ear loop and then administered to the tympanic membrane. For different compositions the administration may vary depending on the mode of polymer assembly. For light-activated networks, in some embodiments, the pre-polymerization solutions are irradiated after placement, for example with a dental during light or any other light source that provides the correct wavelength and intensity specific to the photoinitiator used (e.g. a UV or blue light sensitive gel). Heat sensitive networks may be activated, in some embodiments, by the patient's body temperature upon placement in the ear cavity. pH sensitive gels may be activated, in some embodiments, by the acidic environment in the ear canal following placement. Spontaneously assembling networks may be injected, in some embodiments, via a double-lumen syringe so that the polymer and its initiator are mixed as they are placed at the desired site, for example within the perforation.
- In some embodiments, the methods include enhancing existing otologic treatment methods, such as otologic packing materials or patches. For example, in some embodiments, the pre-polymerized solution may be applied to other surgical materials to enhance their effect such as by providing a drug-delivering modality to packing materials. In other or further embodiments, the pre-polymerized solution may be applied to surgical materials to enhance their adhesive character to the native tissue.
- Examples and methods of use are described herein as a basis for teaching one skilled in the art to employ the invention in any appropriate manner. These examples disclosed herein are not to be interpreted as limiting.
- In laboratory testing, precursors may comprise poly(ethylene glycol) diacrylate of molecular weight 1000 or poly(ethylene glycol) diacrylate of
molecular weight 4000 purchased from Polysciences Inc. (Warrington, Pa.). Albumin from bovine serum (BSA), tetramethylrhodamine conjugate may be purchased from Invitrogen Inc. (Eugene, Oreg.). Drug incorporation and release were tested. Hydrogels were loaded with BSA during the initial crosslinking procedure. A 10% w/v solution of BSA in PBS with pH 7.4 was prepared. Photocrosslinkable solutions of 10% w/v PEG in PBS with 0.5% Irgacure 2959 photoinitiator were prepared. BSA was incorporated into the solutions at 5 wt % to macromer loading. The final solutions were stirred for 15 minutes at 350 rpm. Then 200 μL was pipetted into wells of a 96 well plate. Each construct was irradiated with UV light for 55 sec. The gels were immediately removed from the wells using a spatula and placed in separate vials containing 5 ml of PBS solution. Then the vials were placed in a shaker at 37° C. (50 rpm). At different time points 500 μL of the PBS solution was removed as a sample and replaced with the same amount of PBS. A Hewlett Packard Diode Array Spectrophotometer (model 8452A) was used to evaluate amount of BSA that was released at each time point. - In the clinic, one embodiment of the present invention may comprise the following administration. The patient may be lying down on their side, with their ear under a microscope. This allows the physician to view and work with the tympanic membrane with both hands free. The physician is now able to administer the liquid pre-polymer composition that has been mixed with the desired drugs. The composition can be dropped into the ear with a pipette, much like eardrops are administered. It is likely that the physician will only need tens of microliters of composition to cover the perforation. Once the composition has been added and covers the perforation, the physician can then irradiate the composition with light wherever a hydrogel is needed. Though the unused composition does not need to be aspirated, excess composition may be removed with either a pipette or some absorbent object according to the physician's preference. Any excess of composition can be added to ensure that the perforation is covered by the gel, since all excess composition can be removed. An attachment for the light source (such as a fiber optic cable) may be used to reach the TM of all patients. Since this all takes place under a microscope, the physician is able to be precise in covering the perforation with gel.
- In a surgical setting, one embodiment of the present invention may comprise enhancing current surgical packing materials for the middle ear. The liquid pre-polymer composition that has been mixed with the desired drugs may be dropped onto the packing material and polymerized with light prior to closing the surgical wound. This embodiment would afford the surgical packing material some antibacterial and drug delivery characteristics that it does not currently possess, in addition to enhanced mechanical support, thus improving the post-surgery prognosis.
- In our lab, we monitored the release of the protein bovine serum albumin (BSA) in two UV-cured PEG hydrogels of different molecular weights over a period of three weeks. The data, shown below in Table 2, indicated that the molecular weight of PEG has a direct relationship with drug release. This study confirmed that the amount of released protein can be controlled by changing the molecular weight of the PEG in the hydrogel, and that PEG hydrogels with higher molecular weight can release more BSA than a lower molecular weight PEG hydrogel over the same period of time. These drug release studies also indicated that the rate of protein release increases slightly during the first two weeks, but the changes during this period are not significant, and the protein release can be controlled to stay within the desired range. The techniques used during this preliminary study can be used for all further drug release studies.
-
TABLE 2 Mean values and standard deviations of bovine serum albumin release from PEG hydrogels of two different molecular weights over time. PEG MW 4000PEG MW 1000 Concentration of Standard Concentration of Standard released drug in 0.1 ml Deviation released drug in 0.1 ml Deviation of PBS (mg/ml), Mean Of the of PBS (mg/ml), Mean Of the Value data Value data Day 2 2.36 0.0697 Day 21.12 0.0340 Day 42.41 0.0300 Day 41.60 0.0967 Day 62.62 0.112 Day 61.55 0.0286 Day13 2.87 0.105 Day 131.42 0.325 -
FIG. 1 illustrates the histogram of bovine serum albumin released from PEG hydrogels of two different molecular weights over time. As the molecular weight increases, the pore size of the hydrogel network may also increase. This may result in a larger volume of the drug being released over time. Additionally, the degradation rate of the hydrogel may increase. In some embodiments, it may be desirable to optimize both the release rate of the drug, and the degradation rate of the hydrogel network. We have observed that, over a two-month period, the PEG MW 1000 remained intact but thePEG MW 4000 degraded entirely when both were in a PBS solution (37° C., 50 RPM). Therefore, in certain embodiments requiring full degradation in relative speed, it would be preferable to utilize an embodiment withPEG MW 4000 over PEG MW 1000. The degradation rate may increase when the scaffold is in the presence of cells actively remodeling their environment, such as the tympanic membrane. The degradation rate of the scaffold may change when in other tissues because of a difference in pH or native molecules that either speed up or slow down the degradation rate. For example, a change in degradation rate would probably be most obvious in the digestive tract, where the pH is very different from normal body fluid, and many different molecules for degrading different scaffolds are present. As a counter-example, the degradation rate probably will not change in the vitreous of the eye. - All materials for the remaining examples are from Sigma-Aldrich (St. Louis, Mo.) and used as received unless otherwise stated.
- Chitosan was purified before use. First, a 1 wt % solution of chitosan in 10 vol % acetic acid was vacuum-filtered to remove insoluble particles. Next, the chitosan was precipitated from solution with 1N sodium hydroxide, then centrifuged at 1400 g for 10 min at room temperature. The supernatant was decanted, then water was added in equal volume to the chitosan and the mixture vortexed. The chitosan suspension was dialyzed in water for 2 d, with water changes 3 times/day. After dialysis, the chitosan suspension was lyophilized for 3 d.
- Purified chitosan was dissolved in 1 vol % acetic acid. A volume of methacrylic anhydride equal to 5% of the volume of 1% acetic acid was added to the chitosan solution, and the solution was stirred for 3 d at 55° C. The chitosan solution was dialyzed in water for 2 d with water changes 3 times/day. The dialyzed solution was lyophilized for 3 d.
- The degree of methacrylation of methacrylated chitosan (MeCS) was determined by proton nuclear magnetic resonance spectroscopy, and determined to be ˜40%.
- A similar protocol to add a methacrylate group to hyaluronic acid, a naturally occurring polymer that is very amenable to cell growth, was used as described above in connection with the methacrylation of chitosan. Two different versions of methacrylated hyaluronic acid were synthesized: one with ˜go % degree of methacrylation (MeHA_90) and one with ˜30% (MeHA_30). The synthesis of MeHA took 21 days.
-
-
- Tested polymerization behavior of MeCS and Me HA separately using established system of UV light and UV light-sensitive initiator.
- Purpose: Unfamiliar materials tested with known polymerization systems.
- Result: Both MeCS and MeHA polymerized into an insoluble polymer network in a predictable manner, with increasing stiffness as irradiation time increased.
-
-
- In this example, we aimed for a material that could form a polymer network upon exposure to blue light from a dental curing light.
- Benefits of using blue light from a curing light may include:
- Hand-held curing lights for dental materials are already calibrated for use with living tissue
- Light output optimized for blue light-sensitive photoinitiators
- User-friendly design
- Economical compared to other light sources
- For the first set of experiments, we tried the same initiator system used with dental materials because:
-
- Reagents are FDA-approved.
- Many references are available that characterize the behavior of initiator system.
- Dental curing lights are optimized for dental material initiator system.
- Reagents:
-
- Camphorquinone (CO): a blue light-reactive photoinitiator
- Ethyl 4-dimethylaminobenzoate (EDMAB): an amine catalyst
- 2,6-di-tert butyl-4-methyl phenol (BHT): a free-radical inhibitor
- Methacrylated chitosan (MeCS)
- Methacrylated hyaluronic acid (MeHA_30 and MeHA_90)
- Because the blue light-reactive initiator system of CO/EDMAB is not traditionally used for hydrogel polymerization, we tested several variables as shown in Table 3:
-
TABLE 3 CQ:EDMAB Solvent System Wt % of Polymers Irradiation Time 2:1 Isopropanol/H2O 0.5 60 s 1:1 Ethanol/H2O 1 120 s 1:2 DMSO/H2O 2 180 s Acetic acid/H2O 4 - The solvent system was the main variable to overcome, as neither CQ nor EDMAB are water-soluble.
- For these experiments, the solutions, as shown in Table 4, were mixed and pipetted onto glass cover slips. The curing light was mounted in place with a clamp, and the solutions irradiated for specified times. Gelation was evaluated qualitatively.
-
TABLE 4 Example system. Irradiation Formula Solvent System Time Notes 0.5% Mecs Isopropanol/H2O 60 s Color change upon 1.2% CQ mixing & medium-stiff gel formation 1.2% EDMAB DMSO/H2O 60 s Color change upon 0.05% BHT mixing % some small gel formation Acetic acid/H2O 60 s Some gel formation - With MeCS, we could get some gel formation using the CQ/EDMAB system. However, we were unable to get similar results with either version of MeHA as shown in Table 5 below.
-
TABLE 5 Example system. Irradiation Formula Solvent System Time Notes 1.0% MeHA_90 Acetic acid/H2O 60 s No gel formation 1.2% CQ 1.2% EDMAB 120 s No gel formation 0.05% BHT 180 s No gel formation - Altering the solvent system to something other than water inhibited gel formation with MeHA. Due to this, we switched blue-light photoinitiators.
- Riboflavin monophosphate is a water-soluble version of the vitamin riboflavin. It is also a blue-light photoinitiator that has recently been used to polymerize methacrylated long-chain polymers.
-
-
-
Riboflavin 5′-monophosphate sodium salt (RF): blue light-photoinitiator - Mees
- MeHA
-
- For these experiments, the solvent system was no longer a variable to test. These variables were tested as shown in Table 6
-
TABLE 6 MeCS/MeHA Concentration Wt % of Irradiation or HA of RF Polymers Time 2:1 10 uM 1 60 s 1:1 20 uM 2 120 s 1:2 30 uM 4 180 s - In this experiment, our priority was to get the stiffest gel possible in a reasonable time frame as shown in Table 7 below.
-
TABLE 7 Example system. Irradiation Gel Formation Formula Time (Y/N) Notes 2% Mees 60 s ~ Formed sort-of- gel 2% MeHA_90 120 s Y Stiff gel 30 uM RF 180 s Y* Very stiff gel - Among the different formulations we tested, as shown in Table 8, we assembled a few that formed very stiff gels. Besides the variables tested here, some additional factors that played a role in gelation were: acidity of solution, light intensity, background color of substrate.
-
TABLE 8 Formulas that formed stiff gels. Irradiation Formula Time Notes 2% Mees 180 s Least viscous pre-polymerization solution 2% MeHA_90 of the three. 30 uM RF 2% Mees 180 s Moderately viscous pre-polymerization 2% MeHA_30 solution. 30 uM RF 4% Mees 120 s Very viscous pre-polymerization solution, 30 uM RF but shortest irradiation time required. - Based upon these results, it appears the formulation with 2% MeCS/2% MeHA_90 may be the easiest to eject from a syringe needle.
- Stock solutions were prepared of all reagents and combined to give the final concentrations of the pre-polymerized solution seen in the Table 9 below. Prior to polymerization, the solution had a very viscous consistency, partially due to the association of the positively charged side groups of chitosan and negatively charged side groups of hyaluronic acid (HA).
-
TABLE 9 Composition of pre-polymerized hydrogel patch material. Reagent Concentration Purpose Methacrylated Chitosan 2 wt % Scaffold Hyaluronic Acid 1 wt % Scaffold Riboflavin 5′- monophosphate 30 uM Photoinitiator sodium salt Ciprofloxacin 6 mM Antibiotic - For all applications of the gel patch, the pre-polymerized solution was irradiated for 3 min using a custom light guide (Leoni, Nuremburg, Germany) fitted to a dental curing light (Mini-Blast, First Medica, Greensboro, N.C.) with a power output of 300 mW/
cm 2· - To determine the drug release profile of the gel patch, 50 ul volumes of pre-polymerized material were polymerized with blue light. The resulting gels were incubated in 0.5 wt % lysozyme in water. Samples of the solution were taken at 1, 5, 10, and 15 d to determine the cumulative release of ciprofloxacin over time. The ciprofloxacin concentration of the sample solutions was determined with UV-Vis spectrophometry against a standard curve of known ciprofloxacin concentrations.
- The release of ciprofloxacin was dependent upon the polymer network crosslinking density of the material. In
FIG. 2 , the release of ciprofloxacin is compared between gels consisting of either 2 wt % MeCS or 2 wt % MeCS/1 wt % HA. Because the gel with both MeCS and HA has a higher crosslink density than the gel with only MeCS, the release of ciprofloxacin was significantly slower.FIG. 3 shows the cumulative release of ciprofloxacin over the course of the study. A slower release profile may be advantageous for the material, as it may extend the time window the perforation has to heal without risk of infection. Neither material demonstrated a “burst release” profile—a sudden release of drugs incongruous with the rest of the release profile—confirming that the release of ciprofloxacin can be controlled by crosslink density. - All in vivo work was performed on adult male chinchillas in accordance with a protocol reviewed and accepted by the Institutional Animal Care and Use Committee.
- A pilot study with 4 adult chinchillas (8 tympanic membranes [TMs]) was conducted to first establish the method for consistently inducing a chronic TM perforation. Tympanic membrane perforations were induced using thermal cautery according to an existing model. See, Amolis C P, Jackler R K, Milczuk H, et al. An animal model of chronic tympanic membrane perforation, Otolarngol Head Neck Surg 1992; 106: 47-55, which is herein incorporated by reference in its entirety. A brass wire wrapped around a soldering iron (Radio Shack, Fort Worth, Tex.) served as a thermal cautery device, and perforations were established in the anterior window of the TM. Perforations were examined weekly, and additional cautery was performed on healed TMs. Perforations that persisted for 30 days were considered to be chronic.
- From the pilot study, 75% of perforations induced by thermal cautery persisted for at least 30 days. This method was used to induce perforations in the experimental group of 8 chinchillas. After 30 days, the persistent perforations were comparable in size to what would be present in a human patient receiving the patch.
- The pre-polymerized solution of MeCS, HA, riboflavin monophosphate, and ciprofloxacin were mixed in water and loaded into a syringe. The viscous solution was then ejected onto an ear loop and transferred to the perforation. The material was cured using a dental curing light with the custom light guide. Of the experimental group, the gel patch was initially applied to 2 perforations, with 1 perforation used as a control. The gel-patched perforations were monitored weekly, and the healing rate compared to perforations not patched with the material.
- The gel patch adhered to the perforation site, and was present 3 weeks after implantation. There was evidence of cell ingrowth within the gel, and there has been no incidence of infection or adverse reaction in animals that received the gel patch. The perforation healed four weeks after the gel application. The study suggests that the material may require four weeks to repair chronic perforations in the TM. The perforation that did not receive the gel patch was still persistent.
- It is noted that terms like “preferably,” “commonly,” and “typically” are not utilized herein to limit the scope of the claimed invention or to imply that certain features are critical, essential, or even important to the structure or function of the claimed invention. Rather, these terms are merely intended to highlight alternative or additional features that may or may not be utilized in a particular embodiment of the present invention.
- Detailed descriptions of one or more embodiments are provided herein. It is to be understood, however, that the present invention may be embodied in various forms. Therefore, specific details disclosed herein (even if designated as preferred or advantageous) are not to be interpreted as limiting, but rather are to be used as a basis for the claims and as a representative basis for teaching one skilled in the art to employ the present invention in any appropriate manner.
- A number of embodiments have been described. Nevertheless it will be understood that various modifications may be made without departing from the spirit and scope of the invention. Accordingly, other embodiments are included as part of the invention and may be encompassed by the attached claims. Furthermore, the foregoing description of various embodiments does not necessarily imply exclusion. For example, “some” embodiments, “exemplary” embodiments, or “other” embodiments may include all or part of “some,” “other,” and “further” embodiments within the scope of this invention. In addition not all embodiments include one or more of the listed objects. For example, materials and methods within the scope of the disclosure can also be defined in accordance with the below embodiments.
-
- 1. A scaffold for the promotion of healing tissues in biological organisms wherein the scaffold is initially a liquid and may be cured into a solid; and delivers drugs to promote healing of the perforation.
- 2. The scaffold of
embodiment 1, wherein the scaffold is biodegradable. - 3. The scaffold of
embodiment 2, wherein the scaffold is for otological use. - 4. The scaffold of embodiment 3, wherein the scaffold is for pediatric otological use.
- 5. The scaffold of
embodiment 1, wherein the scaffold provides mechanical support. - 6. The scaffold of
embodiment 1, wherein the scaffold is used in conjunction with other treatments for healing tissues in biological organisms. - 7. The scaffold of
embodiment 1, comprising at least one polymer, at least one substance that results in the scaffold turning into a gel when an environmental change is applied. - 8. The scaffold of embodiment 7, wherein the scaffold forms a hydrogel.
- 9. The scaffold of embodiment 8, wherein the scaffold is a photo-polymerizable hydrogel.
- 10. The scaffold of embodiment 9, wherein the hydrogel polymerizes upon UV light.
- 11. The scaffold of embodiment 9, wherein the hydrogel polymerizes upon visible light.
- 12. The scaffold of embodiment 8, wherein the scaffold is a selectively polymerizable hydrogel.
- 13. The scaffold of embodiment 7, wherein at least one polymer is polyethylene glycol.
- 14. The scaffold of embodiment 7, wherein at least one polymer is hydrophilic.
- 15. The scaffold of embodiment 14, wherein at least one polymer is chitosan.
- 16. The scaffold of embodiment 7, wherein at least one polymer is hyaluronic acid.
- 17. The scaffold of embodiment 7, further comprising a photoinitiator.
- 18. The scaffold of embodiment 17, wherein the substance that results in the scaffold turning to a gel when an environmental change is applied is methacrylate.
- 19. The scaffold of embodiment 17, wherein the substance that results in the scaffold turning to a gel when an environmental change is applied is acrylate.
- 20. The scaffold of embodiment 17, wherein the photoinitiator is selected from the group: Irgacure 2959, eosin Yin conjunction with 1-vinyl-2-pyrrolidinone and triethanolamine, and
riboflavin 5′-monophosphoate salt. - 21. The scaffold of embodiment 7, wherein at least one polymer may have a molecular weight between 100 and 1,000,000 g/mol.
- 22. The scaffold of embodiment 21, wherein at least one polymer has a molecular weight ranging from 1000 g/mol to 4000 g/mol.
- 23. The scaffold of embodiment 22, wherein at least one polymer has a molecular weight of 4000 g/mol.
- 24. The scaffold of embodiment 7, wherein at least one polysaccharide has a molecular weight between 100 and 1,000,000 g/mol.
- 25. The scaffold of embodiment 7, wherein at least one polymer or at least one polysaccharide has deacylation ranging from Oto 100%.
- 26. A method of treating a perforation of the tympanic membrane comprising,
- administering a liquid pre-polymer composition that has been mixed with desired therapeutics,
- covering the perforation with the pre-polymer, and
- irradiating the composition with light wherever a hydrogel is needed.
- 27. The method of embodiment 26, wherein the physician administers tens of microliters of pre-polymer to cover the perforation.
- 28. The method of embodiment 26, further comprising adding an excess of pre-polymer to ensure that the perforation is covered.
- 29. The method of embodiment 26, further comprising using an attachment for the light source.
- 30. The method of embodiment 29, wherein the attachment for the light source is a fiber optic cable.
- 31. A method of enhancing current otologic packing materials or patches comprising,
- administering a packing material to the necessary areas,
- administering a liquid pre-polymer composition that has been mixed with desired therapeutics, and
- irradiating the composition with light wherever a hydrogel is needed.
Claims (20)
1. An injectable liquid composition for administration on an ear drum comprising:
(a) methacrylated chitosan;
(b) a first polymer selected from hyaluronic acid and methacrylated hyaluronic acid;
(c) a solvent; and
(d) an initiator,
wherein prior to activation the composition has a viscosity of at least about 2800 cP, and
wherein when the initiator is activated the injectable liquid composition forms a scaffold.
2. The injectable liquid composition of claim 1 , wherein the methacrylated chitosan is 40% or more methacrylated.
3. The injectable liquid composition of claim 1 , wherein the first polymer is methacrylated hyaluronic acid and the methacrylated hyaluronic acid is at least 90% methacrylated.
4. The injectable liquid composition of claim 1 , wherein the first polymer is methacrylated hyaluronic acid and the methacrylated hyaluronic acid is at least 30% methacrylated.
5. The injectable liquid composition of claim 1 , wherein the initiator is a photoinitiator.
6. The injectable liquid composition of claim 5 , wherein the photoinitiator is 1-[4-(2-hydroxyethoxy)-phenyl]-2-hydroxy-2-methyl-1-propan-1-one; a combination of eosin Y, 1-vinyl-2-pyrrolidinone and triethanolamine; camphorquinone; and riboflavin 5′-monophosphate sodium salt.
7. The injectable liquid composition of claim 1 , wherein the initiator is 30 μM riboflavin 5′-monophosphate sodium salt as initiator
8. The injectable liquid composition of claim 1 , wherein the composition is at least 2% by weight methacrylated chitosan.
9. The injectable liquid composition of claim 1 , wherein the composition is about 4% by weight methacrylated chitosan.
10. The injectable liquid composition of claim 1 , wherein the composition is at least 1% by weight the first polymer.
11. The injectable liquid composition of claim 1 , wherein the solvent is water.
12. The injectable liquid composition of claim 11 , further comprising a therapeutic composition.
13. The composition of claim 12 , wherein the therapeutic composition is an antibiotic.
14. The composition of claim 13 , wherein the antibiotic is ciprofloxacin.
15. A photo-polymerizable, injectable, otological composition comprising:
(a) 2 wt % methacrylated chitosan;
(b) a first polymer selected from at least 1 wt % hyaluronic acid and at least 1 wt % methacrylated hyaluronic acid;
(c) 30 μM riboflavin 5′-monophosphate sodium salt as initiator; and
(d) water as solvent,
wherein the photo-polymerizable, injectable, otological composition has a viscosity of at least about 2800 cP.
16. The liquid pre-polymer composition of claim 15 , wherein the first polymer is methacrylated hyaluronic acid has a degree of methacrylation of at least about 90%.
17. The liquid pre-polymer composition of claim 15 , wherein the first polymer is methacrylated hyaluronic acid has a degree of methacrylation of at least about 30%.
18. The liquid pre-polymer composition of claim 15 , wherein the methacrylated chitosan has a degree of methacrylation of about 40%.
19. The liquid pre-polymer composition of claim 15 , comprising 4% by weight methacrylated chitosan.
20. An injectable photo-polymerizable otological composition comprising:
(a) at least 2% wt methacrylated chitosan;
(b) at least 1% wt hyaluronic acid;
(c) riboflavin 5′-monophosphate sodium salt;
(d) water; and
(e) an antibiotic,
wherein the photo-polymerizable, injectable, otological composition has a viscosity of at least about 2800 cP.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18/131,810 US20230241285A1 (en) | 2012-06-28 | 2023-04-06 | Selectively Polymerizable Compositions and Methods of Use in Vivo |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261665639P | 2012-06-28 | 2012-06-28 | |
PCT/US2013/048385 WO2014004936A1 (en) | 2012-06-28 | 2013-06-28 | Selectively polymerizable compositions and methods of use in vivo |
US14/583,708 US10357591B2 (en) | 2012-06-28 | 2014-12-28 | Selectively polymerizable compositions and methods of use in vivo |
US16/449,430 US20190307916A1 (en) | 2012-06-28 | 2019-06-23 | Selectively polymerizable compositions and methods of use in vivo |
US18/131,810 US20230241285A1 (en) | 2012-06-28 | 2023-04-06 | Selectively Polymerizable Compositions and Methods of Use in Vivo |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/449,430 Continuation US20190307916A1 (en) | 2012-06-28 | 2019-06-23 | Selectively polymerizable compositions and methods of use in vivo |
Publications (1)
Publication Number | Publication Date |
---|---|
US20230241285A1 true US20230241285A1 (en) | 2023-08-03 |
Family
ID=49783883
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/583,708 Active US10357591B2 (en) | 2012-06-28 | 2014-12-28 | Selectively polymerizable compositions and methods of use in vivo |
US16/449,430 Abandoned US20190307916A1 (en) | 2012-06-28 | 2019-06-23 | Selectively polymerizable compositions and methods of use in vivo |
US18/131,810 Pending US20230241285A1 (en) | 2012-06-28 | 2023-04-06 | Selectively Polymerizable Compositions and Methods of Use in Vivo |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/583,708 Active US10357591B2 (en) | 2012-06-28 | 2014-12-28 | Selectively polymerizable compositions and methods of use in vivo |
US16/449,430 Abandoned US20190307916A1 (en) | 2012-06-28 | 2019-06-23 | Selectively polymerizable compositions and methods of use in vivo |
Country Status (13)
Country | Link |
---|---|
US (3) | US10357591B2 (en) |
EP (2) | EP2844309B1 (en) |
JP (2) | JP6456285B2 (en) |
KR (2) | KR20150040817A (en) |
CN (1) | CN104812419B (en) |
AU (2) | AU2013284453A1 (en) |
BR (1) | BR112014032568A2 (en) |
CA (1) | CA2877725C (en) |
DK (1) | DK2844309T3 (en) |
ES (1) | ES2904329T3 (en) |
IL (1) | IL236399B2 (en) |
MX (1) | MX2014015668A (en) |
WO (1) | WO2014004936A1 (en) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104812419B (en) * | 2012-06-28 | 2017-06-09 | 图兰恩教育基金管理人 | Selective polymerisable compound and its in vivo application method |
JP6316943B2 (en) * | 2013-05-15 | 2018-04-25 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | Modulation of heparin-binding epidermal growth factor activity for tympanic membrane healing |
US10376863B2 (en) | 2014-09-30 | 2019-08-13 | Panasonic Intellectual Property Management Co., Ltd. | Gas adsorbent, gas adsorbent manufacturing method, glass panel unit |
FR3026300B1 (en) * | 2014-09-30 | 2020-01-10 | L'oreal | COSMETIC PROCESS TO REDUCE WRINKLES |
WO2017132639A1 (en) * | 2016-01-30 | 2017-08-03 | The Board Of Trustees Of The Leland Stanford Junior University | Light-activated anchoring of therapeutic factors to tissues |
CN106729952B (en) * | 2016-12-23 | 2020-05-22 | 西安交通大学 | PPF/PPF-DA light-cured material bone adhesive tape |
AU2018269057A1 (en) * | 2017-05-18 | 2019-11-07 | The Board Of Trustees Of The Leland Stanford Junior University | Targeted in situ therapeutic delivery of secreted factors from stem cells for treatment of damaged tissue |
CN107383290B (en) * | 2017-08-09 | 2019-11-12 | 成都美益达医疗科技有限公司 | A kind of polyacrylate grafting modified gelatin-adhesive and preparation method thereof |
CN110302425A (en) * | 2019-06-20 | 2019-10-08 | 温州医科大学附属第一医院 | Mix the preparation method and applications of hydrogel biological material |
CN111097070B (en) * | 2020-01-09 | 2021-06-22 | 上海交通大学 | Injectable bioactive hydrogel for inhibiting tumor and promoting repair |
CN113350564B (en) * | 2021-05-20 | 2023-03-10 | 诺一迈尔(苏州)生命科技有限公司 | Biodegradable tissue adhesive patch and preparation method thereof |
WO2024020475A1 (en) * | 2022-07-20 | 2024-01-25 | Tympanogen, Inc. | Photocurable hydrogel compositions |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120289541A1 (en) * | 2010-01-07 | 2012-11-15 | Novartis Ag | Methods and compositions for applying moxifloxacin to the ear |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2356983T3 (en) * | 2000-02-11 | 2011-04-15 | The General Hospital Corporation | PHOTOCHEMICAL TISSULAR UNION. |
US8215314B2 (en) * | 2000-02-11 | 2012-07-10 | The General Hospital Corporation | Photochemical tissue bonding |
US20020151974A1 (en) * | 2001-02-23 | 2002-10-17 | Bonassar Lawrence J. | Tympanic membrane patch |
US7361719B2 (en) * | 2002-01-31 | 2008-04-22 | Micro Science Tech Co., Ltd. | Monomer with anti-microbial character, polymer using the same, and manufacturing method thereof |
WO2006138542A2 (en) * | 2005-06-15 | 2006-12-28 | Surmodics, Inc. | Macromer composition including light activated initiator |
US20090220607A1 (en) * | 2005-09-15 | 2009-09-03 | Kiser Patrick F | Polymeric compositions and methods of making and using thereof |
US20070110788A1 (en) * | 2005-11-14 | 2007-05-17 | Hissong James B | Injectable formulation capable of forming a drug-releasing device |
EP2012803A4 (en) * | 2006-04-20 | 2012-08-01 | Univ Utah Res Found | Polymeric compositions and methods of making and using thereof |
WO2009015124A2 (en) * | 2007-07-23 | 2009-01-29 | Hyperbranch Medical Technology, Inc. | Polymeric masking materials for spanning wound sites, and methods of use thereof |
AU2009240512B2 (en) * | 2008-04-24 | 2014-07-10 | Medtronic, Inc. | Protective gel based on chitosan and oxidized polysaccharide |
MX2010014077A (en) * | 2008-06-26 | 2011-04-05 | Kanemaru Shinichi | Agent for regenerating tympanic membrane or external auditory canal. |
JP2010005230A (en) * | 2008-06-30 | 2010-01-14 | Advance Co Ltd | Biological hard tissue filling material and manufacturing system for the filling material |
CN104812419B (en) * | 2012-06-28 | 2017-06-09 | 图兰恩教育基金管理人 | Selective polymerisable compound and its in vivo application method |
-
2013
- 2013-06-28 CN CN201380035537.5A patent/CN104812419B/en active Active
- 2013-06-28 MX MX2014015668A patent/MX2014015668A/en unknown
- 2013-06-28 KR KR20147037083A patent/KR20150040817A/en active Application Filing
- 2013-06-28 EP EP13808753.1A patent/EP2844309B1/en active Active
- 2013-06-28 JP JP2015520542A patent/JP6456285B2/en not_active Expired - Fee Related
- 2013-06-28 BR BR112014032568A patent/BR112014032568A2/en not_active Application Discontinuation
- 2013-06-28 EP EP21204562.9A patent/EP3995160A1/en not_active Withdrawn
- 2013-06-28 DK DK13808753.1T patent/DK2844309T3/en active
- 2013-06-28 CA CA2877725A patent/CA2877725C/en active Active
- 2013-06-28 KR KR1020207015806A patent/KR102269511B1/en active IP Right Grant
- 2013-06-28 ES ES13808753T patent/ES2904329T3/en active Active
- 2013-06-28 AU AU2013284453A patent/AU2013284453A1/en not_active Abandoned
- 2013-06-28 WO PCT/US2013/048385 patent/WO2014004936A1/en active Application Filing
-
2014
- 2014-12-22 IL IL236399A patent/IL236399B2/en unknown
- 2014-12-28 US US14/583,708 patent/US10357591B2/en active Active
-
2017
- 2017-02-06 AU AU2017200796A patent/AU2017200796B2/en active Active
-
2018
- 2018-02-27 JP JP2018033529A patent/JP2018122111A/en active Pending
-
2019
- 2019-06-23 US US16/449,430 patent/US20190307916A1/en not_active Abandoned
-
2023
- 2023-04-06 US US18/131,810 patent/US20230241285A1/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120289541A1 (en) * | 2010-01-07 | 2012-11-15 | Novartis Ag | Methods and compositions for applying moxifloxacin to the ear |
Non-Patent Citations (2)
Title |
---|
Amsden, Methacrylated Glycol Chitosan as a Photopolymerizable Biomaterial, Biomacromolecules, 2007, 8, 3758-3766 (Year: 2007) * |
Orunto, New Trends on Photopolymers, Practical Holography XXII: Materials and Applicaitons, Vol. 6912, 691207, 2008 (Year: 2008) * |
Also Published As
Publication number | Publication date |
---|---|
IL236399A0 (en) | 2015-02-26 |
AU2017200796A1 (en) | 2017-02-23 |
US20190307916A1 (en) | 2019-10-10 |
US20150112244A1 (en) | 2015-04-23 |
CN104812419B (en) | 2017-06-09 |
KR20200067913A (en) | 2020-06-12 |
JP2015521915A (en) | 2015-08-03 |
MX2014015668A (en) | 2015-07-14 |
EP2844309A1 (en) | 2015-03-11 |
DK2844309T3 (en) | 2022-01-24 |
AU2013284453A1 (en) | 2015-01-22 |
EP3995160A1 (en) | 2022-05-11 |
CA2877725C (en) | 2024-01-02 |
IL236399B2 (en) | 2023-07-01 |
KR20150040817A (en) | 2015-04-15 |
JP2018122111A (en) | 2018-08-09 |
WO2014004936A1 (en) | 2014-01-03 |
EP2844309B1 (en) | 2021-10-27 |
JP6456285B2 (en) | 2019-01-23 |
CN104812419A (en) | 2015-07-29 |
EP2844309A4 (en) | 2016-01-20 |
ES2904329T3 (en) | 2022-04-04 |
KR102269511B1 (en) | 2021-06-24 |
AU2017200796B2 (en) | 2018-12-20 |
IL236399B1 (en) | 2023-03-01 |
BR112014032568A2 (en) | 2017-06-27 |
US10357591B2 (en) | 2019-07-23 |
WO2014004936A8 (en) | 2014-01-30 |
CA2877725A1 (en) | 2014-01-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230241285A1 (en) | Selectively Polymerizable Compositions and Methods of Use in Vivo | |
EP3432933B1 (en) | Biocompatible adhesives and methods of use thereof | |
Liu et al. | Injectable dopamine-modified poly (ethylene glycol) nanocomposite hydrogel with enhanced adhesive property and bioactivity | |
Ferreira et al. | Photocrosslinkable polymers for biomedical applications | |
US20220088264A1 (en) | Bioadhesive hydrogels | |
AU2022231701A1 (en) | Methods and systems for treating a site of a medical implant | |
KR20180075601A (en) | Composite bioadhesive sealant | |
Calder et al. | Thermoresponsive and injectable hydrogel for tissue agnostic regeneration | |
US10736914B2 (en) | Controllably degradable compositions and methods | |
TWI837703B (en) | Photocrosslinked hydrogels blended composition, preparation and use thereof | |
US20230218796A1 (en) | Tissue adhesive for use in a treatment method in which an ophthalmological implant is implanted in a human or animal patient, and ophthalmological implantation system | |
US20180193518A1 (en) | Controllably Degradable Compositions and Methods | |
JP2006043204A (en) | Wound healing acceleration material | |
Pires Moedas De Almeida Barros et al. | Photocurable GelMA adhesives for corneal perforations |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |